PT J
AU Sawada, NO
   Zago, MMF
   Galvao, CM
   Cardozo, FMC
   Zandonai, AP
   Okino, L
   Nicolussi, AC
AF Sawada, Namie Okino
   Fontao Zago, Marcia Maria
   Galvao, Cristina Maria
   Coelho Cardozo, Fernanda Mara
   Zandonai, Alexandra Paola
   Okino, Liyoko
   Nicolussi, Adriana Cristina
TI The Outcomes of Visualization and Acupuncture on the Quality of Life of Adult Cancer Patients Receiving Chemotherapy
SO CANCER NURSING
LA English
DT Article
DE Acupuncture; Cancer; Chemotherapy; Quality of life; Visualization
ID alternative medicine; guided imagery; induced nausea; complementary; relaxation; stimulation; pain
AB Background: The use of complementary and alternative medicine (CAM) to treat cancer patients has increased around the world, and its benefits have been described. These therapies represent an important theme in oncology and have been used in parallel with conventional therapies. Objective: This study aimed to assess the outcomes of using relaxation with visualization and acupuncture on the quality of life of cancer patients undergoing chemotherapy treatment and to compare these outcomes with patients who did not choose to receive the intervention. Methods: Participants chose to be in either the intervention group (IG) or control group (CG). They completed the Quality of Life Questionnaire-Core 30 at the start and end of chemotherapy. The IG was chosen by 38 patients with different types of cancer who completed weekly relaxation with visualization and acupuncture sessions, whereas the CG was composed of 37 patients who did not receive the intervention. Results: Statistically significant results evidenced an increase in global health and emotional and social functions and a decrease in fatigue and loss of appetite for the IG, and an increase in global health for the CG (P <= .05). A highly significant difference was found when comparing the post-chemotherapy scores of the Quality of Life Questionnaire-Core 30 in the global health domain between the CG and the IG (P <= .001), indicating positive outcomes of the CAM intervention. Conclusion: Adults with cancer are able to choose between involvement or not with this kind of CAM intervention. Global health could be improved by participating in this type of intervention. Implications for Practice: Choosing whether to be involved may be assisted by knowing the positive outcomes for some patients.
C1 [Sawada, Namie Okino] Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Coll Nursing Ribeirao Preto, BR-14040902 Sao Paulo, Brazil.
   [Okino, Liyoko] Ctr Univ Barao Maua, Brazilian Assoc Acupuncture, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Sawada, NO (corresponding author), Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Coll Nursing Ribeirao Preto, Av Bandeirantes 3900, BR-14040902 Sao Paulo, Brazil.
EM sawada@eerp.usp.br
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Amorim MH, 1999, ENFERMAGEM PSICONEUR, V0, P0
   Ballatori Enzo, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P46, DOI 10.1186/1477-7525-1-46
   BONASSA EMA, 2000, ENFERMAGEM TERAPEUTI, V0, P0
   BRABO EP, 2006, THESIS UERJ RIO DE J, V0, P0
   Brasil Ministerio da Saude Secretaria de Atencao a Saude BasicaDdA, 2006, POL NAC PRAT INT COM, V0, P0
   BURISH TG, 1992, HEALTH PSYCHOL, V11, P17, DOI 10.1037/0278-6133.11.1.17
   BURISH TG, 1991, J CONSULT CLIN PSYCH, V59, P518, DOI 10.1037/0022-006X.59.4.518
   Chiappelli F, 2005, EVID-BASED COMPL ALT, V2, P453, DOI 10.1093/ecam/neh106
   Cohen M, 2007, RES SOCIAL WORK PRAC, V17, P313, DOI 10.1177/1049731506293741
   Collins Kimberly B, 2004, J AM ACAD NURSE PRACT, V16, P76
   ERNST E, 1995, BRIT J GEN PRACT, V45, P506
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Grant M, 1998, QUALITY LIFE NURSING, V0, P3
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   HART J, 2006, ALTERN COMPLEMENT TH, V12, P208
   HECKER HU, 2007, PRATICA ACUPUNTURA, V0, P0
   HOFFMAN C, 2007, BREAST CANC RES S2, V9, P1
   HOU ZF, 1981, SCI SINICA, V24, P1166
   JIANG D, 1989, B HUNAN MED U, V14, P335
   KOLCABA K, 1992, ONCOL NURS FORUM, V26, P67
   León-Pizarro C, 2007, PSYCHO-ONCOLOGY, V16, P971, DOI 10.1002/pon.1171
   Lopes A, 2008, ONCOLOGIA GRADUACAO, V0, P0
   Lu Weidong, 2007, J SOC INTEGR ONCOL, V5, P1, DOI 10.2310/7200.2006.035
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Luebbert K, 2001, PSYCHO-ONCOLOGY, V10, P490, DOI 10.1002/pon.537
   MA L, 2009, BAYLOR U MED CENT, V22, P138
   Mannix LK, 1999, HEADACHE, V39, P326, DOI 10.1046/j.1526-4610.1999.3905326.x
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   *NAT CTR COMPL ALT, 2004, BKG, V0, PD239
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   PARKMAN HP, 2003, TCM S, V0, P83
   Pert C, 1997, MOL EMOTION, V0, P0
   Polit DF, 2004, FUNDAMENTOS PESQUISA, V5th, P0
   Price S, 2006, INTEGR CANCER THER, V5, P308, DOI 10.1177/1534735406294899
   Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889
   Roscoe JA, 2000, J PAIN SYMPTOM MANAG, V20, P113, DOI 10.1016/S0885-3924(00)00159-7
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Sawada NO, 2009, REV ESC ENFERM USP, V43, P581, DOI 10.1590/S0080-62342009000300012
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   ZHAO X, 1999, ZHEN CI YAN JIU, V0, P17
NR 44
TC 6
Z9 7
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD SEP-OCT 15
PY 2010
VL 33
IS 5
BP E21
EP E28
DI 10.1097/NCC.0b013e3181d86739
PG 8
WC Oncology; Nursing
SC Oncology; Nursing
GA 630YX
UT WOS:000280314000013
PM 20562622
DA 2026-01-16
ER

PT J
AU Meng, ZQ
   Garcia, MK
   Chiang, JS
   Peng, HT
   Shi, YQ
   Fu, J
   Liu, LM
   Liao, ZX
   Zhang, Y
   Bei, WY
   Thornton, B
   Palmer, JL
   McQuade, J
   Cohen, L
AF Meng, Zhi-Qiang
   Garcia, M. Kay
   Chiang, Joseph S.
   Peng, Hui-Ting
   Shi, Ying-Qiang
   Fu, Jie
   Liu, Lu-Ming
   Liao, Zhong-Xing
   Zhang, Ying
   Bei, Wen-Ying
   Thornton, Bob
   Palmer, J. Lynn
   McQuade, Jennifer
   Cohen, Lorenzo
TI Electro-acupuncture to prevent prolonged postoperative ileus: A randomized clinical trial
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Acupuncture; Gastrointestinal motility; Gastrointestinal disorders; Gastrointestinal neoplasms
ID placebo-controlled trial; advanced cancer-patients; major abdominal-surgery; mu-opioid antagonist; phase-iii trial; chronic constipation; double-blind; acupuncture; alvimopan; methylnaltrexone
AB AIM: To examine whether acupuncture can prevent prolonged postoperative ileus (PPOI) after intraperitoneal surgery for colon cancer. METHODS: Ninety patients were recruited from the Fudan University Cancer Hospital, Shanghai, China. After surgery, patients were randomized to receive acupuncture (once daily, starting on postoperative day 1, for up to six consecutive days) or usual care. PPOI was defined as an inability to pass flatus or have a bowel movement by 96 h after surgery. The main outcomes were time to first flatus, time to first bowel movement, and electrogastroenterography. Secondary outcomes were quality of life (QOL) measures, including pain, nausea, insomnia, abdominal distension/fullness, and sense of well-being. RESULTS: No significant differences in PPOI on day 4 (P = 0.71) or QOL measures were found between the groups. There were also no group differences when the data were analyzed by examining those whose PPOI had resolved by day 5 (P = 0.69) or day 6 (P = 0.88). No adverse events related to acupuncture were reported. CONCLUSION: Acupuncture did not prevent PPOI and was not useful for treating PPOI once it had developed in this population. (C) 2010 Baishideng. All rights reserved.
C1 [Meng, Zhi-Qiang; Peng, Hui-Ting; Fu, Jie; Liu, Lu-Ming] Fudan Univ, Canc Hosp, Dept Integrat Oncol, Shanghai 200032, Peoples R China.
   [Garcia, M. Kay] Univ Texas Houston, MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med Integrat Med, Houston, TX 77030 USA.
   [Chiang, Joseph S.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA.
   [Meng, Zhi-Qiang; Shi, Ying-Qiang; Fu, Jie; Liu, Lu-Ming; Zhang, Ying; Bei, Wen-Ying] Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Shi, Ying-Qiang] Fudan Univ, Canc Hosp, Dept Abdominal Surg, Shanghai 200032, Peoples R China.
   [Liao, Zhong-Xing] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Zhang, Ying; Bei, Wen-Ying] Fudan Univ, Canc Hosp, Int Ctr Integrat Oncol, Shanghai 200032, Peoples R China.
   [Thornton, Bob] Univ Texas Houston, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA.
   [Palmer, J. Lynn; Cohen, Lorenzo] Univ Texas Houston, MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA.
   [McQuade, Jennifer] Univ Texas Houston, MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA.
C3 Fudan University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas Health Science Center Houston; Fudan University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas Health Science Center Houston
RP Liu, LM (corresponding author), Fudan Univ, Canc Hosp, Dept Integrat Oncol, Shanghai 200032, Peoples R China.
EM llm1010@163.com
FU US National Cancer Institute (NCI) [CA108084, CA12153031]
CR Balestrini JL, 2005, SCAND J GASTROENTERO, V40, P734, DOI 10.1080/00365520510015719
   Barker P, 1984, J R COLL SURG EDINB, V29, P147
   BASIKA R, 2000, 26 IVAS C VET AC REL, V0, P0
   BONACINI M, 1993, AM J GASTROENTEROL, V88, P208
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Chen S F, 1994, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V14, P406
   Chen X, 1996, HUA XI YI KE DA XUE XUE BAO, V27, P418
   CONDON RE, 1986, ANN SURG, V203, P574, DOI 10.1097/00000658-198605000-00019
   Crowell MD, 2007, NAT CLIN PRACT GASTR, V4, P484, DOI 10.1038/ncpgasthep0899
   DAI JL, 1993, CHINESE MED J-PEKING, V106, P220
   Deadman P, 1999, A MANUAL OF ACUPUNCTURE, V0, P0
   Delaney CP, 2005, DIS COLON RECTUM, V48, P1114, DOI 10.1007/s10350-005-0035-7
   Delaney CP, 2005, DIS COLON RECTUM, V48, P1127
   Diehl DL, 1999, J ALTERN COMPLEM MED, V5, P27, DOI 10.1089/acm.1999.5.27
   Dill S G, 1992, PROBL VET MED, V4, P144
   DISBROW EA, 1993, WESTERN J MED, V158, P488
   FERRAZ AAB, 1995, AM SURGEON, V61, P1079
   Johanson JF, 2008, AM J GASTROENTEROL, V103, P170, DOI 10.1111/j.1572-0241.2007.01524.x
   Jorgensen H, 2000, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001893
   KELLEY MC, 1993, AM J SURG, V165, P107, DOI 10.1016/S0002-9610(05)80412-X
   KLAUSER AG, 1993, Z GASTROENTEROL, V31, P605
   Kraft MD, 2008, EXPERT OPIN INV DRUG, V17, P1365, DOI 10.1517/13543784.17.9.1365
   LI YY, 1992, AM J GASTROENTEROL, V87, P1372
   Lin XM, 1997, AM J GASTROENTEROL, V92, P1527
   Lin Zhiyue, 2002, CRIT REV BIOMED ENG, V30, P419, DOI 10.1615/CritRevBiomedEng.v30.i456.70
   LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233
   Maron DJ, 2008, AM J THER, V15, P59, DOI 10.1097/MJT.0b013e31804c6f37
   McCallum RW, 1996, AM J MED SCI, V312, P19, DOI 10.1097/00000441-199607000-00004
   MILLER RD, 1990, ANESTHESIA, V0, P0
   Nekolaichuk CL, 1999, J CLIN ONCOL, V17, P3621, DOI 10.1200/JCO.1999.17.11.3621
   Nekolaichuk CL, 1999, PALLIATIVE MED, V13, P311, DOI 10.1191/026921699675854885
   Pocock StuartJ, 2013, CLIN TRIALS PRACTICA, V0, P0
   Ponec RJ, 1999, NEW ENGL J MED, V341, P137, DOI 10.1056/NEJM199907153410301
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   SCULATI O, 1982, J INT MED RES, V10, P194, DOI 10.1177/030006058201000310
   SCULATI O, 1980, LANCET, V1, P1252
   Stewart David, 2007, AM J THER, V14, P561, DOI 10.1097/MJT.0b013e31804bdf54
   Tan EK, 2007, ALIMENT PHARM THER, V25, P47, DOI 10.1111/j.1365-2036.2006.03150.x
   TATSUTA M, 1993, ALIMENT PHARM THERAP, V7, P459
   Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377
   TOLLESSON PO, 1991, ACTA CHIR-EUR J SURG, V157, P355
   TOLLESSON PO, 1991, SCAND J GASTROENTERO, V26, P477, DOI 10.3109/00365529108998569
   Traut U, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004930.pub3
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   WALDHAUSEN JHT, 1990, ANN SURG, V212, P671, DOI 10.1097/00000658-199012000-00004
   WITTE CL, 1993, WESTERN J MED, V158, P532
   Wolff BG, 2007, J AM COLL SURGEONS, V204, P609, DOI 10.1016/j.jamcollsurg.2007.01.041
   YEO CJ, 1993, ANN SURG, V218, P229, DOI 10.1097/00000658-199309000-00002
   Yuan CS, 2002, J PHARMACOL EXP THER, V300, P118, DOI 10.1124/jpet.300.1.118
NR 49
TC 61
Z9 72
U1 2
U2 43
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JAN 7
PY 2010
VL 16
IS 1
BP 104
EP 111
DI 10.3748/wjg.v16.i1.104
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 542CE
UT WOS:000273468100014
PM 20039456
DA 2026-01-16
ER

PT J
AU Kim, KH
   Lee, MS
   Choi, SM
   Ernst, E
AF Kim, Kun Hyung
   Lee, Myeong Soo
   Choi, Sun-Mi
   Ernst, Edzard
TI Acupuncture for Treating Uremic Pruritus in Patients with End-Stage Renal Disease: A Systematic Review
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Review
DE Acupuncture; end-stage renal disease; systematic review; uremic pruritus; itching
ID double-blind; bias; itch; hemodialysis; analgesia; location; therapy; trials; diary
AB Uremic pruritus (UP) is a common and bothersome symptom in end-stage renal disease (ESRD) that does not always respond to conventional care. Acupuncture is frequently used for the treatment of a wide range of conditions, but its effects on UP in ESRD patients are unclear. The objective of this review was to evaluate the effectiveness of acupuncture for UP in patients with ESRD. We searched 16 electronic databases from their inception to November 2009. All prospective clinical studies of needle acupuncture for UP in hemodialysis patients with ESRD were included regardless of their design. Risk of bias of the included studies was assessed using the Cochrane criteria. Three randomized controlled trials and three uncontrolled observational studies were included. All of the included trials reported beneficial effects of acupuncture. However; most of the studies showed high risk of bias, which leaves their reports unconvincing. The current evidence is insufficient to show that acupuncture is an effective treatment for UP in patients with ESRD because of suboptimal quality and lack of methodological rigor of included studies. Future trials should overcome the limitations of the currently available evidence. J Pain Symptom Manage 2010;40:117-125. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Kim, Kun Hyung; Lee, Myeong Soo; Choi, Sun-Mi] Korea Inst Oriental Med, Acupuncture Moxibust & Meridian Res Ctr, Taejon 305811, South Korea.
   [Lee, Myeong Soo; Ernst, Edzard] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
   [Lee, Myeong Soo; Ernst, Edzard] Univ Plymouth, Exeter, Devon, England.
C3 Korea Institute of Oriental Medicine (KIOM); University of Exeter; University of Plymouth
RP Lee, MS (corresponding author), Korea Inst Oriental Med, Div Standard Res, Taejon 305811, South Korea.
EM drmslee@gmail.com
FU Korea Institute of Oriental Medicine [K09050]
CR CARMICHAEL AJ, 1991, LANCET, V337, P1225, DOI 10.1016/0140-6736(91)92898-C
   Carmichael P, 2000, QUAL LIFE RES, V9, P195, DOI 10.1023/A:1008933621829
   Chen Chung-Jen, 2003, DERMATOL THER, V16, P87
   Chou CY, 2005, NEPHROL DIAL TRANSPL, V20, P1912, DOI 10.1093/ndt/gfh955
   DICKERSIN K, 1998, JAMA-J AM MED ASSOC, V263, P1385
   DUO LJ, 1987, NEPHRON, V47, P179, DOI 10.1159/000184487
   Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0
   Gao Hongmei, 2002, J TRADIT CHIN MED, V22, P29
   Garcia GE, 2005, ADV CHRONIC KIDNEY D, V12, P282, DOI 10.1016/j.ackd.2005.04.002
   Han JB, 2008, ACUPUNCTURE ELECTRO, V33, P145, DOI 10.3727/036012908803861168
   Iliev E, 1998, CLIN DERMATOL, V16, P659, DOI 10.1016/S0738-081X(98)00057-1
   JULIAN PTH, 2008, COCHRANE HDB SYSTEMA, V0, P137
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Keithi-Reddy SR, 2007, KIDNEY INT, V72, P373, DOI 10.1038/sj.ki.5002197
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Manenti L, 2009, DRUGS, V69, P251, DOI 10.2165/00003495-200969030-00002
   Marcus SM, 2006, STAT MED, V25, P2762, DOI 10.1002/sim.2405
   Maunsell E, 2000, CANCER-AM CANCER SOC, V88, P2387, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2387::AID-CNCR25>3.3.CO;2-G
   Millikan Larry E, 2003, DERMATOL THER, V16, P175
   National Center for Complementary and Alternative Medicine, 2007, INTR AC, V0, P0
   Patel TS, 2007, AM J KIDNEY DIS, V50, P11, DOI 10.1053/j.ajkd.2007.03.010
   Pauli-Magnus C, 2000, J AM SOC NEPHROL, V11, P514, DOI 10.1681/ASN.V113514
   Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461
   Pittler MH, 2000, J CLIN EPIDEMIOL, V53, P485, DOI 10.1016/S0895-4356(99)00220-6
   Rei HR, 2002, CHIN ACUPUNCTURE MOXIBUSTION, V22, P235
   RICHARDSON A, 1994, J ADV NURS, V19, P782, DOI 10.1111/j.1365-2648.1994.tb01151.x
   SAKURABA H, 2007, NIHON TOSEKI IGAKKAI, V40, P513
   Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4
   Schwartz IF, 2000, SEMIN DIALYSIS, V13, P177, DOI 10.1046/j.1525-139x.2000.00050.x
   SHAPIRO RS, 1986, AM J ACUPUNCTURE, V14, P235
   SHERMAN RA, 2007, HDB DIALYSIS, V0, P179
   STAHLEBACKDAHL M, 1995, SEMIN DERMATOL, V14, P297
   WAHLGREN CF, 1995, SEMIN DERMATOL, V14, P277, DOI 10.1016/S1085-5629(05)80048-3
   Wikström B, 2005, J AM SOC NEPHROL, V16, P3742, DOI 10.1681/ASN.2005020152
   Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   ZHOU J, 2002, ZHONGGUO ZHEN JIU, V22, P518
   Zucker I, 2003, J AM ACAD DERMATOL, V49, P842, DOI 10.1016/S0190-9622(03)02478-2
NR 40
TC 48
Z9 58
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL 15
PY 2010
VL 40
IS 1
BP 117
EP 125
DI 10.1016/j.jpainsymman.2009.11.325
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 629PA
UT WOS:000280210900020
PM 21796811
DA 2026-01-16
ER

PT J
AU Adams, R
   White, B
   Beckett, C
AF Adams, Rose
   White, Barb
   Beckett, Cynthia
TI The effects of massage therapy on pain management in the acute care setting.
SO International journal of therapeutic massage & bodywork
LA English
DT Journal Article
DE Massage therapy; Swedish effleurage; acupressure; acute care; anxiety; cancer; craniosacral; fibromyalgia; hospital; inpatients; pain management; patient care management; postoperative pain; pregnancy; reflexology; relaxation; research
AB BACKGROUND: Pain management remains a critical issue for hospitals and is  receiving the attention of hospital accreditation organizations. The acute care  setting of the hospital provides an excellent opportunity for the integration of  massage therapy for pain management into the team-centered approach of patient  care. PURPOSE AND SETTING: This preliminary study evaluated the effect of the use  of massage therapy on inpatient pain levels in the acute care setting. The study  was conducted at Flagstaff Medical Center in Flagstaff, Arizona-a nonprofit  community hospital serving a large rural area of northern Arizona. METHOD: A  convenience sample was used to identify research participants. Pain levels before  and after massage therapy were recorded using a 0 - 10 visual analog scale.  Quantitative and qualitative methods were used for analysis of this descriptive  study. PARTICIPANTS: Hospital inpatients (n = 53) from medical, surgical, and  obstetrics units participated in the current research by each receiving one or  more massage therapy sessions averaging 30 minutes each. The number of sessions  received depended on the length of the hospital stay. RESULT: Before massage, the  mean pain level recorded by the patients was 5.18 [standard deviation (SD):  2.01]. After massage, the mean pain level was 2.33 (SD: 2.10). The observed  reduction in pain was statistically significant: paired samples t(52) = 12.43, r  = .67, d = 1.38, p < .001. Qualitative data illustrated improvement in all areas,  with the most significant areas of impact reported being overall pain level,  emotional well-being, relaxation, and ability to sleep. CONCLUSIONS: This study  shows that integration of massage therapy into the acute care setting creates  overall positive results in the patient's ability to deal with the challenging  physical and psychological aspects of their health condition. The study  demonstrated not only significant reduction in pain levels, but also the  interrelatedness of pain, relaxation, sleep, emotions, recovery, and finally, the  healing process.
C1 Therapy Services, Massage Therapy;
NR 0
TC 0
SN 1916-257
EI 
J9 Int J Ther Massage Bodywork
PD JAN 1
PY 2010
VL 3
IS 1
BP 4
EP 11
DI 
PG 7
UT PubMed:21589696
PM 21589696
DA 2010-01-01
ER

PT J
AU Lu, W
   Posner, MR
   Wayne, P
   Rosenthal, DS
   Haddad, RI
AF Lu, Weidong
   Posner, Marshall R
   Wayne, Peter
   Rosenthal, David S
   Haddad, Robert I
TI Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a
SO Integrative cancer therapies
LA English
DT Journal Article
AB BACKGROUND: Dysphagia is a common side effect following chemoradiation therapy  (CRT) in patients with head and neck cancer (HNC). METHODS: In this retrospective  case series, 10 patients with HNC were treated with acupuncture for  radiation-induced dysphagia and xerostomia. All patients were diagnosed with  stage III/IV squamous cell carcinoma. In all, 7 of 10 patients were percutaneous  endoscopic gastrostomy (PEG) tube dependent when they began acupuncture. Manual  acupuncture and electroacupuncture were used once a week. RESULTS: A total of 9  of 10 patients reported various degrees of subjective improvement in swallowing  functions, xerostomia, pain, and fatigue levels. Overall, 6 (86%) of 7 PEG  tube-dependent patients had their feeding tubes removed after acupuncture, with a  median duration of 114 days (range 49 to 368 days) post CRT. One typical case is  described in detail. CONCLUSIONS: A relatively short PEG tube duration and  reduced symptom severity following CRT were observed in these patients. Formal  clinical trials are required to determine the causality of the observations.
C1 Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. weidong_lu@dfci.harvard.edu
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD AUG 18
PY 2010
VL 9
IS 3
BP 284
EP 90
DI 10.1177/1534735410378856
PG -194
WC Acupuncture Therapy; Adult; Aged; Carcinoma, Squamous Cell; drug therapy; Combined Modality Therapy; adverse effects; Deglutition; Deglutition Disorders; etiology; Enteral Nutrition; Female; Gastrostomy; Head and Neck Neoplasms; drug therapy; Humans; Intubation, Gastrointestinal; Male; Middle Aged
UT PubMed:20713374
PM 20713374
DA 2010-08-18
ER

PT J
AU Tuck, CM
AF Tuck, Claire M.
TI A 54-year-old woman with degenerative back pain
SO ACUPUNCTURE IN MEDICINE
LA English
DT Editorial Material
ID acupuncture
AB Back pain is a common symptom: up to 70% of UK adults experience this symptom by the age of 60 and most have moderate to severe pain. Back pain accounted for 12% of consultations to traditional acupuncturists in 2001 and is one of the most common reasons for consultation with an acupuncturist. This case report concerns a 54-year-old woman with metastatic breast cancer and degenerative lower back pain, which remained painful despite intensive pharmaceutical management and facet joint injection and was ultimately successfully managed with two 30 min acupuncture treatments 2 weeks apart, using eight points on the BL meridians. Acupuncture treatment using tender points was later trialled for neuropathic pain secondary to local recurrence in her mastectomy scar, however this was unsuccessful and inpatient hospice admission for further intensive pharmaceutical management was required.
C1 Strathcarron Hosp, Denny FK6 5HJ, Stirlingshire, England.
RP Tuck, CM (corresponding author), Strathcarron Hosp, Randolph Hill, Denny FK6 5HJ, Stirlingshire, England.
EM clairetuck@nhs.net
CR AUNG S, 1994, ACUPUNCT MED, V12, P37
   DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C
   *END PHARM, 2009, LID 5 PATCH PRESCR I, V0, P0
   Freynhagen R, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b3002
   Furlan AD, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001351.pub2
   Hempenstall K, 2005, PLOS MED, V2, P628, DOI 10.1371/journal.pmed.0020164
   Kotani N, 2001, REGION ANESTH PAIN M, V26, P532, DOI 10.1053/rapm.2001.25897
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   *NHS CLIN KNWOL SU, 2009, BAK PAIN LOW RAD, V0, P0
   Prady Stephanie L, 2007, ACUPUNCT MED, V25, P121
   Redfearn T, 1992, ACUPUNCT MED, V10, P73
   *SIGN, 2008, CONTR CANC PAIN SIGN, V0, P0
   Spiller Juliet, 2007, ACUPUNCT MED, V25, P109
   Yuan J, 2008, COMPLEMENT THER MED, V16, P295, DOI 10.1016/j.ctim.2008.04.006
NR 18
TC 3
Z9 5
U1 0
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 
J9 ACUPUNCT MED
JI Acupunct. Med.
PD MAR 15
PY 2010
VL 28
IS 1
BP 46
EP 48
DI 10.1136/aim.2009.000687
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 665DH
UT WOS:000283014900011
PM 20351378
DA 2026-01-16
ER

PT J
AU Mahfudh, SS
AF Mahfudh, Salma Said
TI Historical perspectives and trends in the management of pain for cancer patients
SO Asian Pacific journal of cancer prevention : APJCP
LA English
DT Journal Article
AB INTRODUCTION: Sultanate of Oman is the second largest country in the Gulf, with a  population of 2,867,428 (2008) of which 35.2% is under 15 years and only 3.7%  above 65 years. Incidence of newly diagnosed cancers is also the second highest  in the Gulf with 11%. Research conducted between 1997-2007 revealed that the most  frequent cancers in males: stomach 10%, non-Hodgkins lymphoma 8.6% and prostate  7% while in females: breast 18.9%, thyroid 8.3% and cervix uteri 6.5%. A  population-based registry was established in 1996 to compile an accurate database  and monitor cancer trends. There is a rigorous follow up of reported cases.  Unfortunately most patients report at the hospitals in advanced stages which  complicate pain management. All treatment modalities of cancer are available in  Oman at the two centers, Royal Hospital and SQUH. There is a continuous effort to  develop national educational guidelines, protocols for cancer treatment,  palliative care and pain management (PM). HISTORICAL PERSPECTIVES AND TRENDS IN  THE MANAGEMENT OF PAIN: In 1970s Omanis used traditional medicine, wassam  (moxibustion), to treat pain. In 1988 severe pain was treated in hospitals with  intramuscular opioid, whenever necessary (PRN). 1989 SQUH approved use of both  parenteral and oral narcotics, received its first consignment, and started PM.  The Ministry of Health (MOH) was concerned with possible misuse and for 8 years,  thereafter, SQUH was the only hospital allowed to import, stock, prescribe and  dispense oral narcotics. Legal requirement to obtain opioids in Oman involves MOH  and World Health Organization (WHO) and there is a control as to who can  prescribe for both inpatient and outpatient. The drugs available to control pain  include non opioids, weak opioids, but the only strong opioids used for severe  cancer pain are morphine and Fentanyl. This is complemented with adjuvant drugs.  We use the "WHO Ladder" to guide us in the management of pain. Three different  cases have been presented to see how PM of cancer patients has evolved from using  only non-opioid in 1993, to using intramuscular pethidine in 1995, then to using  morphine with adjuvants in 1999. Referral of patients to the PM Team has improved  the pain control and at present even without referral, pain is controlled more  effectively. CONCLUSION: There is no doubt that the Sultanate of Oman has  progressed tremendously since 1970. The Government is working very hard and is  taking major steps to improve cancer care in order to meet the International  Bench Mark. Each 5 year plan focuses on actual needs. One of the important needs  that have been addressed is the management of pain which has significantly  improved. Factors that have improved PM in Oman include the introduction of the  PM Teams, training of Nurses and Doctors, follow up of the PM services in the  clinical areas, authorizing MOH hospitals to use oral opioids, opening of the  National Oncology Centre with Radiation Therapy, inter institutional discussions  and development of guidelines, implementation of WHO Guidelines on PM and audits,  peer reviews and research.
C1 Sultan Qaboos University Hospital, POBox 38, Code 123, Al Khodh, Sultanate of Oman.
NR 0
TC 0
SN 2476-762
EI 
J9 Asian Pac J Cancer Prev
PD APR 1
PY 2010
VL 11 Suppl 1
IS 
BP 93
EP 6
DI 
PG -87
WC Analgesics, Opioid; therapeutic use; Fentanyl; therapeutic use; Humans; Morphine; therapeutic use; Neoplasms; drug therapy; Oman; Pain; drug therapy
UT PubMed:20590357
PM 20590357
DA 2010-04-01
ER

PT J
AU Smith, CA
   Carmady, B
AF Smith, Caroline A
   Carmady, Bridget
TI Acupuncture to treat common reproductive health complaints: An overview of the
SO Autonomic neuroscience : basic & clinical
LA English
DT Journal Article
AB BACKGROUND: Women specific health complaints are common, and women are higher  users of complementary therapies and medicines. Acupuncture is one modality used  by women. The aim of this paper was to summarise the evidence from scientific  trials and systematic reviews assessing the effectiveness of acupuncture to treat  the most common women specific reproductive health complaints. METHODS: We  conducted a search of the major databases PubMed, CINAHL, and the Cochrane  Library from their inception to Sept 2009, to obtain English language texts of  randomised controlled trials (RCTs) and systematic reviews. The following English  Australian search terms were used: acupuncture and period pain or dysmenorrhea,  or premenstrual syndrome, or poly cystic ovarian syndrome/PCOS, or menstrual  headache, or irregular periods/menstruation, or amenorrhea, or heavy  menses/periods, or menorrhagia, or menopause, and randomised controlled trial and  systematic review. Both authors extracted data and reviewed each trial and  systematic review for methodological quality. RESULTS: Five systematic reviews  were included, and six RCTs. The symptoms of the menopause and dysmenorrhea have  been subject to greater clinical evaluation through RCTs, and the evidence  summarised in systematic reviews, than any other reproductive health complaint.  The evidence for acupuncture to treat dysmenorrhea and menopause remains unclear,  due to small study populations and the presence of methodological bias.  Acupuncture to treat PMS, PCOS and other menstrual related symptoms is  under-studied, and the evidence for acupuncture to treat these conditions is  frequently based on single studies. CONCLUSION: Further research is needed.
C1 Centre for Complementary Medicine Research, The University of Western Sydney, Locked Bag 1797, Penrith South, NSW 1797, Australia. caroline.smith@uws.edu.au
NR 0
TC 0
SN 1872-748
EI 
J9 Auton Neurosci
PD MAY 21
PY 2010
VL 157
IS 1-2
BP 52
EP 6
DI 10.1016/j.autneu.2010.03.013
PG -46
WC Acupuncture Therapy; methods; Databases, Factual; statistics & numerical data; Dysmenorrhea; therapy; Female; Humans; Polycystic Ovary Syndrome; therapy; Premenstrual Syndrome; therapy; Randomized Controlled Trials as Topic
UT PubMed:20483671
PM 20483671
DA 2010-05-21
ER

PT J
AU Hopkins, Hollis AS
AF Hopkins Hollis, Anne Seton
TI Acupuncture as a treatment modality for the management of cancer pain: the state
SO Oncology nursing forum
LA English
DT Review
AB PURPOSE/OBJECTIVES: To explore the current state of the science regarding  acupuncture as a treatment modality for cancer pain. DATA SOURCES: PubMed and  CINAHL databases were searched, as were Web sites from the National Cancer  Institute, the National Institute of Health's Complementary and Alternative  Medicine Program, and the American Cancer Society. DATA SYNTHESIS: This article  synthesizes nine years of published research on the use of acupuncture as an  adjunct treatment for the management of cancer pain. CONCLUSIONS: Findings  suggest a lack of level I evidence regarding the use of acupuncture as a cancer  pain treatment modality. The majority of evidence is level III or higher;  therefore, causality cannot be inferred. IMPLICATIONS FOR NURSING: Future  research should focus on level I and level II evidence, controlling for variables  to strengthen validity, and addressing sample size to enhance the  generalizability of results. Nurses should be knowledgeable about the state of  the science evidence available to assist patients in making educated decisions.
C1 School of Nursing, Johns Hopkins University, Baltimore, MD, USA. ahopkin9@son.jhmi.edu
NR 0
TC 0
SN 1538-068
EI 
J9 Oncol Nurs Forum
PD AUG 28
PY 2010
VL 37
IS 5
BP E344
EP 8
DI 10.1188/10.ONF.E344-E348
PG 1
WC Acupuncture Therapy; nursing; Humans; Neoplasms; nursing; Pain; nursing; Pain Management; Randomized Controlled Trials as Topic
UT PubMed:20797942
PM 20797942
DA 2010-08-28
ER

PT J
AU Rehberg, B
AF Rehberg, Benno
TI Evidence-based integrative pain medicine
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Pain; Evidence-based practice; Placebo; Cancer pain; Neuropathic pain; Low back pain; Fibromyalgia; Integrative medicine
ID low-back-pain; alternative medicine; interventional therapy; complementary therapy; fibromyalgia; acupuncture; guidelines; stimulation; management; surgery
AB Integrative medicine is already, consciously or unconsciously, widely practised in pain medicine. However, a large part of practised pain medicine is not evidence-based. In this article, the evidence for different forms of conventional pain therapy (pharmacological, psychological, physical and interventional) as well as CAM for the pain conditions cancer pain, neuropathic pain, low back pain, and fibromyalgia syndrome is reviewed. The literature search comprised only randomised controlled trials (RCTs) and systematic reviews or guideline publications in which the quality of the included studies is analysed according to predefined criteria. Except for cancer pain, evidence is lacking for both conventional and alternative therapies, and conventional therapy is often not sufficiently efficacious. A multimodal/multidisciplinary approach seems appropriate and integration of CAM in this approach is facilitated by the similarity of the bio-psycho-social model of chronic pain with the mind-body models of many forms of CAM. In addition, placebo-controlled studies may not be always necessary due to the fact that the placebo effect is also therapeutic in pain therapy ("therabo"). Instead, different forms of therapy may be directly compared in RCTs, accompanied by cost-effectiveness and cost-utility studies. However, pain therapy is still a long way from having an evidence-based therapy option for every patient. (C) 2010 Elsevier GmbH. All rights reserved.
C1 [Rehberg, Benno] Charite, Dept Anesthesiol CCM CVK, D-10117 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Rehberg, B (corresponding author), Hop Univ Geneve, Dept APSIC, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.
EM benno.rehberg-klug@hcuge.ch
CR Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3
   Arnold B, 2009, SCHMERZ, V23, P112, DOI 10.1007/s00482-008-0741-x
   Artus M, 2007, BMC FAM PRACT, V8, P0, DOI 10.1186/1471-2296-8-26
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Barnes P, 2007, 12 CDC, V0, P2007
   Bennett R, 2006, NAT CLIN PRACT RHEUM, V2, P416, DOI 10.1038/ncprheum0245
   Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522
   Chou R, 2009, SPINE, V34, P1078, DOI 10.1097/BRS.0b013e3181a103b1
   Chou R, 2009, SPINE, V34, P1066, DOI 10.1097/BRS.0b013e3181a1390d
   Chuck A, 2009, VALUE HEALTH, V12, PA166, DOI 10.1016/S1098-3015(10)73894-8
   Cruccu G, 2007, EUR J NEUROL, V14, P952, DOI 10.1111/j.1468-1331.2007.01916.x
   CRUCCU G, 2007, OFFICIAL J WORLD I P, V7, P230
   Fleckenstein J, 2009, BMC COMPLEM ALTERN M, V9, P0, DOI 10.1186/1472-6882-9-31
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Häuser W, 2009, DTSCH ARZTEBL INT, V106, P383, DOI 10.3238/arztebl.2009.0383
   Holdcraft LC, 2003, BEST PRACT RES CL RH, V17, P667, DOI 10.1016/S1521-6942(03)00037-8
   Jones KD, 2006, HEALTH QUAL LIFE OUT, V4, P0, DOI 10.1186/1477-7525-4-67
   Karjalainen K, 2003, COCHRANE DATABASE SYST REV, V0, PP2, DOI 10.1002/14651858.CD002193
   Karjalainen K A, 1999, COCHRANE DATABASE OF SYSTEMATIC REVIEWS, V0, P0, DOI DOI 10.1002/14651858.CD001984
   Keller A, 2007, EUR SPINE J, V16, P1776, DOI 10.1007/s00586-007-0379-x
   Kerns RD, 2004, J PAIN, V5, P357, DOI 10.1016/j.jpain.2004.06.005
   Khadilkar A, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003008.pub3
   Langhorst J, 2008, SCHMERZ, V22, P324, DOI 10.1007/s00482-008-0677-1
   Machado LAC, 2009, RHEUMATOLOGY, V48, P520, DOI 10.1093/rheumatology/ken470
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Manchikanti L, 2009, PAIN PHYSICIAN, V12, P699
   Martin-Sanchez Eva, 2009, OPEN RHEUMATOL J, V3, P25, DOI 10.2174/1874312900903010025
   Mayhew E, 2007, RHEUMATOLOGY, V46, P801, DOI 10.1093/rheumatology/kel406
   MILNE S, 2001, COCHRANE DB SYST REV, V0, P0
   Moseley GL, 2004, PAIN, V108, P192, DOI 10.1016/j.pain.2004.01.006
   OConnell NE, 2009, SPINE, V34, P752, DOI 10.1097/BRS.0b013e31819d06f3
   OConnor AB, 2009, AM J MED, V122, PS22, DOI 10.1016/j.amjmed.2009.04.007
   Parr AT, 2009, PAIN PHYSICIAN, V12, P163
   Patrick DL, 2004, J NATL CANCER INST M, V32, P9
   Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231
   Robb K, 2009, J PAIN SYMPTOM MANAG, V37, P746, DOI 10.1016/j.jpainsymman.2008.03.022
   Rosenberg EI, 2008, PAIN MED, V9, P1065, DOI 10.1111/j.1526-4637.2008.00477.x
   Sommer C, 2008, SCHMERZ, V22, P313, DOI 10.1007/s00482-008-0676-2
   Turner JA, 2004, PAIN, V108, P137, DOI 10.1016/j.pain.2003.12.016
   van Koulil S, 2007, ANN RHEUM DIS, V66, P571, DOI 10.1136/ard.2006.054692
   van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/00007632-200306150-00014
   Yuan J, 2008, SPINE, V33, PE887, DOI 10.1097/BRS.0b013e318186b276
   Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005
NR 43
TC 5
Z9 7
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD SEP 15
PY 2010
VL 2
IS 3
BP 109
EP 113
DI 10.1016/j.eujim.2010.06.001
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 708EW
UT WOS:000286346000002
DA 2026-01-16
ER

PT J
AU Cassileth, BR
   Keefe, FJ
AF Cassileth, Barrie R.
   Keefe, Francis J.
TI Integrative and Behavioral Approaches to the Treatment of Cancer-Related Neuropathic Pain
SO ONCOLOGIST
LA English
DT Article
DE Acupuncture; Pain; Cancer; Psychological stress; Behavioral medicine; Integrative medicine; Complementary therapies
ID acupuncture; therapy
AB Integrative oncology is the synthesis of mainstream cancer care and evidence-based complementary therapies. Complementary strategies include massage therapies, acupuncture, fitness, and mind-body techniques, which take advantage of the reciprocal relationship between the mind and body. Neuropathic pain-and pain more generally-is part of a complex process involving the whole physical and psychosocial being, therefore requiring an integrative management approach. Several studies have demonstrated, for example, that social context plays an important role in the perception of pain and that a patient's coping strategies can influence the persistence of pain. In this article, we briefly describe research illustrating the promise of integrative approaches for the treatment of cancer-related neuropathic pain. The Oncologist 2010; 15(suppl 2): 19-23
C1 [Keefe, Francis J.] Duke Univ, Med Ctr, Duke Pain Prevent & Treatment Res Program, Durham, NC 27705 USA.
   [Cassileth, Barrie R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
C3 Duke University; Memorial Sloan Kettering Cancer Center
RP Keefe, FJ (corresponding author), Duke Univ, Med Ctr, Duke Pain Prevent & Treatment Res Program, Suite 340,2200 Main St, Durham, NC 27705 USA.
EM keefe003@mc.duke.edu
FU NIH [R01 CA131148, R01 CA100771]
CR Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chan BL, 2007, NEW ENGL J MED, V357, P2206, DOI 10.1056/NEJMc071927
   Dawidson I, 1998, LIFE SCI, V63, P659, DOI 10.1016/S0024-3205(98)00317-8
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Ehde DM, 2004, REHABIL PSYCHOL, V49, P254, DOI 10.1037/0090-5550.49.3.254
   Jensen MP, 2009, INT J CLIN EXP HYP, V57, P239, DOI 10.1080/00207140902881007
   Jensen TS, 2009, CURR OPIN NEUROL, V22, P467, DOI 10.1097/WCO.0b013e3283311e13
   Kaptchuk TJ, 2000, THE WEB THAT HAS NO WEAVER: UNDERSTANDING CHINESE MEDICINE, V2, P1
   Lake Alvin E 3rd, 2006, CURR PAIN HEADACHE REP, V10, P4, DOI 10.1007/s11916-006-0002-6
   Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623
   Pfister DG, 2008, J CLIN ONCOL, V26, P4701, DOI 10.1200/JCO.2008.17.3682
   Pollo A, 2009, PROG BRAIN RES, V175, P283, DOI 10.1016/S0079-6123(09)17520-9
   Santiago-Figueroa J, 2009, P R HEALTH SCI J, V28, P289
   Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59
   *US C, 1990, FIN ACC CANC TREATM, V0, P175
   Vickers Andrew J, 2005, BMC PALLIAT CARE, V4, P5, DOI 10.1186/1472-684X-4-5
   Vickers Andrew J, 2006, BMC ANESTHESIOL, V6, P5, DOI 10.1186/1471-2253-6-5
   Zaza C, 2002, J PAIN SYMPTOM MANAG, V24, P526, DOI 10.1016/S0885-3924(02)00497-9
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 23
TC 38
Z9 48
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAY 15
PY 2010
VL 15
IS 
BP 19
EP 23
DI 10.1634/theoncologist.2009-S504
PG 5
WC Oncology
SC Oncology
GA 599NL
UT WOS:000277919900005
PM 20489193
DA 2026-01-16
ER

PT J
AU Yu, JM
   Qu, PS
   Fan, H
   Wang, Z
   Jin, YB
   Tao, F
AF Yu, Jian-ming
   Qu, Pi-sheng
   Fan, Hao
   Wang, Zhen
   Jin, Ya-bei
   Tao, Fan
TI [Observation on the analgesic effect of transcutaneous electrical acupoint
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
AB OBJECTIVE: To observe the analgesic effect of transcutaneous electrical acupoint  stimulation (TEAS) in assisting general anesthesia (GA) for radical operation of  breast carcinoma so as to explore its clinical application value. METHODS: Sixty  patients scheduled for radical operations of the breast carcinoma were randomly  and equally divided into GA group and TEAS+ GA group. For GA, Propofol [4.5  microg/mL, target concentration; (3.0 +/- 0.5) microg/mL during operation] was  used in combination with Sufentanil (0.25 microg/kg) and Cis-atracurium amine  (0.2 mg/kg). TEAS (5-10 mA, 2 Hz/100 Hz) was applied to Hegu (LI 4)-Laogong (PC  8) and Neiguan (PC 6)-Waiguan (SJ 5) on the affected side of the body for 30 min.  Heart rate (HR), mean aterial pressure (MAP), tube removing time and  postoperative complications were recorded. Plasma beta-endorphin content was  assayed by radioimmunoassay. RESULTS: After anesthesia, patients with reduction  in MAP in GA group were significantly more than those in TEAS+GA group (P <  0.05), and their HR decreased remarkably (P < 0.05). After tracheal intubation,  MAP in TEAS+GA group kept relatively stable, which was superior to that of GA  group (P < 0.05). In comparison with GA group, the patients' analepsia time and  tube withdrawal time of TEAS+ GA group were significantly shorter; and the dosage  of analgesics of TEAS+GA group was significantly smaller than that of GA group (P  < 0.05). Patients with complications of pain, restlessness, drowsiness, nausea  and vomitting were obviously fewer in TEAS + GA group than those in GA group.  Compared with GA group, plasma beta-endorphin content in TEAS+GA group increased  considerably 30 min after TEAS, 5 min after skin-incision and after operation (P  < 0.05). CONCLUSION: TEAS combined with general anesthesia for breast radical  carcinoma operation can help keep a stable blood pressure during surgery, reduce  the dosage of analgesics and strengthen pain relief. The analgesic effect of TEAS  may be related to its effect in up-regulating plasma beta-endorphin level.
C1 Medicine Hospital of Zhejiang, Hangzhou 310003, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAY 13
PY 2010
VL 35
IS 1
BP 43
EP 6
DI 
PG -37
WC Acupuncture Points; Adult; Aged; Anesthesia; Breast Neoplasms; surgery; Carcinoma; surgery; Female; Humans; Middle Aged; Pain Management; Transcutaneous Electric Nerve Stimulation; Young Adult
UT PubMed:20458906
PM 20458906
DA 2010-05-13
ER

PT J
AU Zhang, X
   Fan, XN
   Ding, L
   Zhang, HT
   Wu, LZ
   Wang, HR
AF Zhang, Xue
   Fan, Xiao-Nong
   Ding, Luo
   Zhang, Hai-Tao
   Wu, Lian-Zhong
   Wang, Hai-Rong
TI [Acupuncture treatment of regulating spirit, activating blood and relieving pain
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
AB OBJECTIVE: To compare the clinical effect of acupuncture treatment and western  medicine Carbamazepine for thalamic pain. METHODS: Crossover trial design was  used, 11 cases diagnosed as thalamic pain were randomly divided into two groups  according to the mini-unbalance-index method, group I (with 6 cases received  acupuncture first and then western medicine) and group II (with 5 cases received  western medicine first and then acupuncture). When the effects were evaluated,  the two groups were named as acupuncture group and western medicine group, 11  cases in each group. The method of clearing away the heart fire, regulating the  spirit, activating blood and relieving pain was adopted in acupuncture treatment,  Ximen (PC 4), Yinxi (HT 6), Xuehai (SP 10) and Zhaohai (KI 6) were selected; the  western medicine group was treated with oral administration of Carbamazepine, and  one course as well as the eluting period were both 10 days. The effects were  evaluated with visual analogue scale (VAS) and evaluation scale of Anderson  Cancer Center pain in US (MD Pain Evaluation value) respectively. RESULTS: The  VAS and MD value in two groups were obviously decreased after treatment (both P <  0.05), while there was no significant difference between two groups; the markedly  effective rate of pain relieving in acupuncture group was 63.6% (7/11), which was  higher than that of 36.4% (4/11) in western medicine group, but there was no  significant difference between two groups. CONCLUSION: Acupuncture treatment of  regulating spirit, activating blood and relieving pain has a better therapeutic  effect for thalamic pain, and can reach to the same therapeutic effect with  western medicine Carbamazepine.
C1 Tianjin University of TCM, Tianjin 300193, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 4
PY 2010
VL 30
IS 5
BP 367
EP 70
DI 
PG -297
WC Acupuncture Therapy; Adult; Aged; Blood Circulation; Carbamazepine; therapeutic use; Cross-Over Studies; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Pain; physiopathology; Pain Management; Pain Measurement; Spirituality; Thalamus; physiopathology
UT PubMed:20518170
PM 20518170
DA 2010-06-04
ER

PT J
AU Ernst, E
AF Ernst, Edzard
TI Complementary therapies for supportive cancer care
SO SUPPORTIVE CARE IN CANCER
LA English
DT Editorial Material
ID acupuncture; efficacy; massage; relief; pain
C1 Univ Exeter, Peninsula Med Sch, Exeter EX2 4NT, Devon, England.
C3 University of Exeter
RP Ernst, E (corresponding author), Univ Exeter, Peninsula Med Sch, 25 Victoria Pk Rd, Exeter EX2 4NT, Devon, England.
EM Edzard.Ernst@pms.ac.uk
CR Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Bradt J, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007169.pub3
   Conn VS, 2006, SUPPORT CARE CANCER, V14, P699, DOI 10.1007/s00520-005-0905-5
   Cramp F, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006145.pub2
   Dimeo F, 2004, DEUT Z SPORTMED, V55, P177
   Ernst E, 2008, J POSTGRAD MED, V54, P214, DOI 10.4103/0022-3859.41806
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ernst E, 2006, DESKTOP GUIDE COMPLE, V0, P0
   Fellowes D, 2004, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858
   Klein Joan, 2004, BR J COMMUNITY NURS, V9, P383
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee MS, 2007, ACTA ONCOL, V46, P717, DOI 10.1080/0284160701261584
   Lee MS, 2007, SUPPORT CARE CANCER, V15, P597, DOI 10.1007/s00520-007-0221-3
   Lee MS, 2009, SUPPORT CARE CANCER, V17, P763, DOI 10.1007/s00520-009-0589-3
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Molassiotis A, 2009, COMPLEMENT THER MED, V17, P92, DOI 10.1016/j.ctim.2008.11.002
   Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889
   Roffe L, 2004, J CLIN ONCOL, V22, P4418, DOI 10.1200/JCO.2004.02.034
   Seers HE, 2009, SUPPORT CARE CANCER, V17, P1159, DOI 10.1007/s00520-008-0565-3
   Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P292, DOI 10.1159/000234904
NR 21
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV 15
PY 2010
VL 18
IS 11
BP 1365
EP 1366
DI 10.1007/s00520-010-0991-x
PG 2
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 654QG
UT WOS:000282182500001
PM 20803036
DA 2026-01-16
ER

PT J
AU English, RE
   Chen, JH
AF English, R E
   Chen, J H
TI Stereotactic core biopsy of an impalpable screen-detected breast lesion using
SO The British journal of radiology
LA English
DT Journal Article
AB Chinese acupuncture-analgesia is used for pain management during various surgical  procedures. Over the past 40 years this approach has been introduced in many  countries and has been particularly helpful in the investigation and treatment of  patients who are unable to tolerate conventional analgesia. We report here the  case of a woman with a 17-year history of myalgic encephalitis who underwent a  stereotactic core biopsy of the breast under acupuncture-analgesia. A planning  session was needed to assess the patient's existing condition and her response to  acupuncture. During this session, a range of frequencies for electrical  stimulation of the acupuncture needles using electro-acupuncture apparatus was  determined. We describe the combined acupuncture and biopsy procedures and the  patient's impressions and outcomes are recorded.
C1 Oxford Breast Imaging Centre, Churchill Hospital, Oxford Radcliffe Hospitals NHS Trust, Old Road, Headington, Oxford, UK. ruth.english@orh.nhs.uk
NR 0
TC 0
SN 1748-880
EI 0007-128
J9 Br J Radiol
PD SEP 18
PY 2010
VL 83
IS 994
BP e208
EP 10
DI 10.1259/bjr/20216505
PG 1
WC Acupuncture Analgesia; methods; Biopsy, Needle; Breast Neoplasms; pathology; Carcinoma, Intraductal, Noninfiltrating; pathology; Electroacupuncture; methods; Female; Humans; Middle Aged; Pain; psychology; Pain Management; Patient Satisfaction
UT PubMed:20846978
PM 20846978
DA 2010-09-18
ER

PT J
AU Cho, HJ
   Jeong, YJ
   Park, KK
   Park, YY
   Chung, IK
   Lee, KG
   Yeo, JH
   Han, SM
   Bae, YS
   Chang, YC
AF Cho, Hyun-Ji
   Jeong, Yun-Jeong
   Park, Kwan-Kyu
   Park, Yoon-Yub
   Chung, Il-Kyung
   Lee, Kwang-Gill
   Yeo, Joo-Hong
   Han, Sang-Mi
   Bae, Young-Seuk
   Chang, Young-Chae
TI Bee venom suppresses PMA-mediated MMP-9 gene activation via JNK/p38 and NF-κB-dependent mechanisms
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Bee venom; Phospho-p38; Phospho-JNK; NF-kappa B; MMP-9; MCF-7 cells
ID cells in-vitro; matrix metalloproteinases; carcinoma-cells; matrix-metalloproteinase-9 expression; acupuncture point; down-regulation; tumor invasion; melanoma-cells; cancer; inhibition
AB Ethnopharmacological relevance: Bee venom has been used for the treatment of inflammatory diseases such as rheumatoid arthritis and for the relief of pain in traditional oriental medicine. Aim of the study: The purpose of this study is to elucidate the effects of bee venom on MMP-9 expression and determine possible mechanisms by which bee venom relieves or prevents the expression of MMP-9 during invasion and metastasis of breast cancer cells. We examined the expression and activity of MMP-9 and possible signaling pathway affected in PMA-induced MCF-7 cells. Material and methods: Bee venom was obtained from the National Institute of Agricultural Science and Technology of Korea. Matrigel invasion assay, wound-healing assay, zymography assay, western blot assay, electrophoretic mobility shift assay and luciferase gene assay were used for assessment. Results: Bee venom inhibited cell invasion and migration, and also suppressed MMP-9 activity and expression, processes related to tumor invasion and metastasis, in PMA-induced MCF-7 cells. Bee venom specifically suppressed the phosphorylation of p38/JNK and at the same time, suppressed the protein expression, DNA binding and promoter activity of NF-kappa B. The levels of phosphorylated ERK1/2 and c-Jun did not change. We also investigated MMP-9 inhibition by melittin, apamin and PLA(2), representative single component of bee venom. We confirmed that PMA-induced MMP-9 activity was significantly decreased by melittin, but not by apamin and phospholipase A(2). These data demonstrated that the expression of MMP-9 was abolished by melittin, the main component of bee venom. Conclusion: Bee venom inhibits PMA-induced MMP-9 expression and activity by inhibition of NF-kappa B via p38 MAPK and JNK signaling pathways in MCF-7 cells. These results indicate that bee venom can be a potential anti-metastatic and anti-invasive agent. This useful effect may lead to future clinical research on the anti-cancer properties of bee venom. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Cho, Hyun-Ji; Bae, Young-Seuk] Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, Taegu 702701, South Korea.
   [Cho, Hyun-Ji; Jeong, Yun-Jeong; Park, Kwan-Kyu; Park, Yoon-Yub; Chang, Young-Chae] Catholic Univ Daegu, Sch Med, Res Inst Biomed Engn, Taegu 705718, South Korea.
   [Cho, Hyun-Ji; Jeong, Yun-Jeong; Park, Kwan-Kyu; Park, Yoon-Yub; Chang, Young-Chae] Catholic Univ Daegu, Sch Med, Dept Med, Taegu 705718, South Korea.
   [Chung, Il-Kyung] Catholic Univ Daegu, Dept Biotechnol, Gyongsan 712702, South Korea.
   [Lee, Kwang-Gill; Yeo, Joo-Hong; Han, Sang-Mi] Natl Inst Agr Sci & Technol, Dept Agr Biol, Suwon 441100, Kyunggi Do, South Korea.
C3 Kyungpook National University (KNU); Catholic University of Daegu; Catholic University of Daegu; Catholic University of Daegu
RP Bae, YS (corresponding author), Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, 1370 Sankyuk Dong, Taegu 702701, South Korea.
EM ysbae@knu.ac.kr; ycchang@cu.ac.kr
FU Rural Development Administration, Republic of Korea [20070301-034-001]
CR Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7
   Bhoopathi P, 2008, J BIOL CHEM, V283, P1545, DOI 10.1074/jbc.M707931200
   Cho HJ, 2007, CARCINOGENESIS, V28, P1104, DOI 10.1093/carcin/bgl217
   Chu ST, 2007, LIFE SCI, V80, P364, DOI 10.1016/j.lfs.2006.09.024
   Chung TW, 2004, FASEB J, V18, P1670, DOI 10.1096/fj.04-2126com
   Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788
   Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973
   Holle L, 2003, INT J ONCOL, V22, P93
   Hong IK, 2005, EXP MOL MED, V37, P230, DOI 10.1038/emm.2005.31
   Hong S, 2005, J BIOL CHEM, V280, P25202, DOI 10.1074/jbc.M413985200
   Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, PL1444, DOI 10.1152/ajplung.2001.281.6.L1444
   Itoh T, 1998, CANCER RES, V58, P1048
   Jang HS, 2005, J ETHNOPHARMACOL, V99, P157, DOI 10.1016/j.jep.2005.02.026
   Jang MH, 2003, J PHARMACOL SCI, V91, P95, DOI 10.1254/jphs.91.95
   Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6
   Kato Y, 2002, ONCOL REP, V9, P565
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Lee SO, 2008, BIOCHEM BIOPH RES CO, V366, P1019, DOI 10.1016/j.bbrc.2007.12.068
   Lee YJ, 2007, CHEM-BIOL INTERACT, V169, P189, DOI 10.1016/j.cbi.2007.06.036
   Li B, 2006, ONKOLOGIE, V29, P367, DOI 10.1159/000094711
   Lin CW, 2008, CARCINOGENESIS, V29, P1807, DOI 10.1093/carcin/bgn162
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Liu X, 2002, J PHARM PHARMACOL, V54, P1083, DOI 10.1211/002235702320266235
   Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027
   Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Rahman KMW, 2006, MOL CANCER THER, V5, P2747, DOI 10.1158/1535-7163.MCT-06-0221
   ROUYER N, 1994, INVAS METAST, V14, P269
   Sato T, 2002, CANCER RES, V62, P1025
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731
   Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200
   Tu WC, 2008, TOXICON, V52, P318, DOI 10.1016/j.toxicon.2008.06.007
   Weng CJ, 2008, CARCINOGENESIS, V29, P147, DOI 10.1093/carcin/bgm261
   Zeigler ME, 1999, J CELL PHYSIOL, V180, P271
NR 38
TC 54
Z9 57
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0378-8741
EI 
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD FEB 17
PY 2010
VL 127
IS 3
BP 662
EP 668
DI 10.1016/j.jep.2009.12.007
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 569UV
UT WOS:000275628600013
PM 19969058
DA 2026-01-16
ER

PT J
AU Mahfudh, SS
AF Mahfudh, Salma Said
TI Historical Perspectives and Trends in the Management of Pain for Cancer Patients in Oman
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Cancer pain; management; Sultanate of Oman; WHO guidelines
AB Introduction. Sultanate of Oman is the second largest country in the Gulf, with a population of 2,867,428 (2008) of which 35.2% is under 15 years and only 3.7% above 65 years. Incidence of newly diagnosed cancers is also the second highest in the Gulf with 11%. Research conducted between 1997-2007 revealed that the most frequent cancers in males: stomach 10%, non-Hodgkins lymphoma 8.6% and prostate 7% while in females: breast 18.9%, thyroid 8.3% and cervix uteri 6.5%. A population-based registry was established in 1996 to compile an accurate database and monitor cancer trends. There is a rigorous follow up of reported cases. Unfortunately most patients report at the hospitals in advanced stages which complicate pain management. All treatment modalities of cancer are available in Oman at the two centers, Royal Hospital and SQUH. There is a continuous effort to develop national educational guidelines, protocols for cancer treatment, palliative care and pain management (PM). Historical Perspectives and Trends in the Management of Pain. In 1970s Omanis used traditional medicine, wassam (moxibustion), to treat pain. In 1988 severe pain was treated in hospitals with intramuscular opioid, whenever necessary (PRN). 1989 SQUH approved use of both parenteral and oral narcotics, received its first consignment, and started PM. The Ministry of Health (MOH) was concerned with possible misuse and for 8 years, thereafter, SQUH was the only hospital allowed to import, stock, prescribe and dispense oral narcotics. Legal requirement to obtain opioids in Oman involves MOH and World Health Organization (WHO) and there is a control as to who can prescribe for both inpatient and outpatient. The drugs available to control pain include non opioids, weak opioids, but the only strong opioids used for severe cancer pain are morphine and Fentanyl. This is complemented with adjuvant drugs. We use the "WHO Ladder" to guide us in the management of pain. Three different cases have been presented to see how PM of cancer patients has evolved from using only non-opioid in 1993, to using intramuscular pethidine in 1995, then to using morphine with adjuvants in 1999. Referral of patients to the PM Team has improved the pain control and at present even without referral, pain is controlled more effectively. Conclusion. There is no doubt that the Sultanate of Oman has progressed tremendously since 1970. The Government is working very hard and is taking major steps to improve cancer care in order to meet the International Bench Mark. Each 5 year plan focuses on actual needs. One of the important needs that have been addressed is the management of pain which has significantly improved. Factors that have improved PM in Oman include the introduction of the PM Teams, training of Nurses and Doctors, follow up of the PM services in the clinical areas, authorizing MOH hospitals to use oral opioids, opening of the National Oncology Centre with Radiation Therapy, inter institutional discussions and development of guidelines, implementation of WHO Guidelines on PM and audits, peer reviews and research.
C1 SQUH, Nursing Directorate, Al Khoud, Oman.
C3 Sultan Qaboos University
RP Mahfudh, SS (corresponding author), SQUH, Nursing Directorate, POB 38,Code 123, Al Khoud, Oman.
CR *MOH, 2008, OM CANC REP, V0, P0
   *SULT OM MOH, 2008, ANN HLTH REP SULT OM, V0, P0
NR 5
TC 4
Z9 4
U1 0
U2 11
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI NAGOYA
PA 4-84 JOTO-CHO, KITA-KU, NAGOYA, 462-0831, JAPAN
SN 1513-7368
EI 
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PD APR 15
PY 2010
VL 11
IS 
BP 93
EP 96
DI 
PG 4
WC Oncology
SC Oncology
GA 682DK
UT WOS:000284379900016
PM 20590357
DA 2026-01-16
ER

PT J
AU Hervik, J
   Mjåland, O
AF Hervik, Jill
   Mjåland, Odd
TI Quality of life of breast cancer patients medicated with anti-estrogens, 2 years
SO International journal of women's health
LA English
DT Journal Article
DE anti-estrogen medication; breast cancer; quality of life
AB OBJECTIVE: The aim of this study was to examine the quality of life of breast  cancer patients medicated with estrogen antagonists, 2 years after having  acupuncture treatment for hot flashes. METHODS AND MATERIALS: Our sample was  taken from women who had recently participated in a randomized controlled trial  investigating the effects of acupuncture on hot flashes, a side effect of  estrogen-antagonist treatment. Forty-one women from the true acupuncture  treatment group and 41 women from the control group (sham acupuncture), who had 2  years previously received a course of 15 acupuncture treatments over a period of  10 weeks, were asked to answer an open question. The question, "Would you like to  share your thoughts and experiences related to your breast cancer diagnosis,  treatments or anything else?" was by being open, broad, and nonspecific, intended  to stimulate subjective information, which was not included in the original, or  future quantitative studies. Qualitative data were analyzed using systematic text  condensation. RESULTS: Most women were troubled by two or more side effects due  to anti-estrogen medication, negatively affecting their life quality. Symptoms  included hot flashes, sleep problems, muscle and joint pain, arm edema, fatigue,  weight gain, depression, and lack of sexual desire. Women previously treated with  sham acupuncture complained that hot flashes were still problematic, whilst those  previously treated with traditional Chinese acupuncture found them less of a  problem and generally had a more positive outlook on life. These results compare  favorably with the findings from our original study that measured quantitatively  health related quality of life. CONCLUSION: Side effects due to anti-estrogen  treatment seriously affect the quality of life of breast cancer operated  patients. Patients who had previously been treated with traditional Chinese  acupuncture complained less of hot flashes, and had a more positive outlook on  life, than women who had previously been treated with sham acupuncture.
C1 Pain Clinic, Vestfold Hospital, Tønsberg, Norway. jill.hervik@siv.no
NR 0
TC 0
SN 1179-141
EI 
J9 Int J Womens Health
PD DEC 15
PY 2010
VL 2
IS 
BP 319
EP 25
DI 10.2147/IJWH.S12809
PG -294
UT PubMed:21151679
PM 21151679
DA 2010-12-15
ER

PT J
AU O'Regan, D
   Filshie, J
AF O'Regan, David
   Filshie, Jacqueine
TI Acupuncture and cancer
SO AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
LA English
DT Article
DE Acupuncture; Cancer
ID radiation-induced xerostomia; auricular acupuncture; different frequency; point stimulation; pain; electroacupuncture; acupressure; nausea; chemotherapy; brain
AB Acupuncture has become a popular complementary treatment in oncology, particularly as patients seek non-pharmacological alternatives to provide symptom control. A considerable body of evidence suggests that acupuncture modulates neurological processes to bring about its effects. This basic research is supported by an increasing number of positive clinical studies of varying quality. Lower quality studies have hampered the widespread acceptability of acupuncture, with some deeming the inter-personal skills of the practitioner to be more powerful than the needle or its equivalent. More recent randomised control trials (RCTs) have sought to settle this controversy, with mixed results. The literature was searched to identify, where possible, RCTs involving acupuncture and various common cancer symptoms. A potential role for acupuncture was found in the following cancer symptoms: pain, nausea and vomiting, xerostomia, hot flushes, fatigue, anxiety, depression and insomnia. Acupuncture is safe with minimal side-effects, and is clinically effective for the management of these symptoms. Continuing research using validated methodology is essential. In the interim, health professionals should be open to explore the use of acupuncture with their cancer patients. (C) 2010 Published by Elsevier B.V.
C1 [Filshie, Jacqueine] Royal Marsden Hosp, London SW3 6JJ, England.
   Royal Marsden Hosp, Surrey, England.
C3 Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust
RP Filshie, J (corresponding author), Royal Marsden Hosp, London SW3 6JJ, England.
EM jacqueline.filshie@btinternet.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Cheuk DKL, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005375.pub2
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Davies AN, 2002, ORAL ONCOL, V38, P680, DOI 10.1016/S1368-8375(01)00133-6
   Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Duan DM, 2009, J TRADIT CHIN MED, V29, P167, DOI 10.1016/S0254-6272(09)60057-1
   Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Filshie J, 2006, ANESTHESIOL CLIN N A, V24, P81, DOI 10.1016/j.atc.2005.12.008
   Filshie J, 1996, PALLIATIVE MED, V10, P145, DOI 10.1177/026921639601000209
   Filshie J, 2009, OXFORD TXB PALLIATIV, V0, P772
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Frisk J, 2009, EUR UROL, V55, P156, DOI 10.1016/j.eururo.2008.02.002
   Furlan AD, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001351.pub2
   Garcia MK, 2009, HEAD NECK-J SCI SPEC, V31, P1360, DOI 10.1002/hed.21110
   Green S, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005319
   Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169-328X(96)00170-2
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   LEE A, 2009, COCHRANE DATABASE SY, V15, P0
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   LEE JH, 1993, PAIN, V52, P11, DOI 10.1016/0304-3959(93)90109-3
   Leo RJ, 2007, J AFFECT DISORDERS, V97, P13, DOI 10.1016/j.jad.2006.06.012
   Lu Weidong, 2007, J SOC INTEGR ONCOL, V5, P1, DOI 10.2310/7200.2006.035
   Lundeberg T, 1999, ACUPUNCTURE SCI APPR, V0, P93
   Maa SH, 2003, J ALTERN COMPLEM MED, V9, P659, DOI 10.1089/107555303322524517
   Maa SH, 2007, J CLIN NURS, V16, P794, DOI 10.1111/j.1365-2702.2005.01515.x
   MANHEIMER E, 2010, COCHRANE DATABASE SY, V20, P0
   Mann F, 2000, REINVENTING ACUPUNCTURE: A NEW CONCEPT OF ANCIENT MEDICINE, V2nd, P0
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Minton O, 2008, JNCI-J NATL CANCER I, V100, P1155, DOI 10.1093/jnci/djn250
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Trinh KV, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004870.pub3
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vickers Andrew J, 2005, BMC PALLIAT CARE, V4, P5, DOI 10.1186/1472-684X-4-5
   WALKER EM, 2009, J CLIN ONCOL, V0, P0
   White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413
   White A, 2008, AN INTRODUCTION TO WESTERN MEDICAL ACUPUNCTURE, V0, P0
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   Wright Leonard D, 2005, AM J HOSP PALLIAT CARE, V22, P49, DOI 10.1177/104990910502200111
   Wu HS, 2004, J ADV NURS, V45, P252, DOI 10.1046/j.1365-2648.2003.02886.x
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 68
TC 55
Z9 65
U1 1
U2 57
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1566-0702
EI 1872-7484
J9 AUTON NEUROSCI-BASIC
JI Auton. Neurosci-Basic Clin.
PD OCT 28
PY 2010
VL 157
IS 1-2
BP 96
EP 100
DI 10.1016/j.autneu.2010.05.001
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 679SX
UT WOS:000284182200017
PM 20605536
DA 2026-01-16
ER

PT J
AU Cassileth, BR
   Keefe, FJ
AF Cassileth, Barrie R
   Keefe, Francis J
TI Integrative and behavioral approaches to the treatment of cancer-related
SO The oncologist
LA English
DT Review
AB Integrative oncology is the synthesis of mainstream cancer care and  evidence-based complementary therapies. Complementary strategies include massage  therapies, acupuncture, fitness, and mind-body techniques, which take advantage  of the reciprocal relationship between the mind and body. Neuropathic pain--and  pain more generally--is part of a complex process involving the whole physical  and psychosocial being, therefore requiring an integrative management approach.  Several studies have demonstrated, for example, that social context plays an  important role in the perception of pain and that a patient's coping strategies  can influence the persistence of pain. In this article, we briefly describe  research illustrating the promise of integrative approaches for the treatment of  cancer-related neuropathic pain.
C1 Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
NR 0
TC 0
SN 1549-490
EI 
J9 Oncologist
PD MAY 28
PY 2010
VL 15 Suppl 2
IS 
BP 19
EP 23
DI 10.1634/theoncologist.2009-S504
PG 4
WC Acupuncture Therapy; Cognitive Behavioral Therapy; Humans; Hypnosis; Massage; Neoplasms; complications; Neuralgia; etiology
UT PubMed:20489193
PM 20489193
DA 2010-05-28
ER

PT J
AU Lu, W
   Rosenthal, DS
AF Lu, Weidong
   Rosenthal, David S
TI Recent advances in oncology acupuncture and safety considerations in practice.
SO Current treatment options in oncology
LA English
DT Journal Article
AB Oncology acupuncture is a new and emerging field of research. Recent advances  from published clinical trials have added evidence to support the use of  acupuncture for symptom management in cancer patients. Recent new developments  include (1) pain and dysfunction after neck dissection; (2) radiation-induced  xerostomia in head and neck cancer; (3) aromatase inhibitor-associated arthralgia  in breast cancer; (4) hot flashes in breast cancer and prostate cancer; and (5)  chemotherapy-induced neutropenia in ovarian cancer. Some interventions are  becoming a non-pharmaceutical option for cancer patients, while others still  require further validation and confirmation. Meanwhile, owing to the rapid  development of the field and increased demands from cancer patients, safety  issues concerning oncology acupuncture practice have become imperative. Patients  with cancer may be at higher risk developing adverse reactions from acupuncture.  Practical strategies for enhancing safety measures are discussed and recommended.
C1 Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, SW560, 44 Binney Street, Boston, MA 02115, USA. Weidong_lu@dfci.harvard.edu
NR 0
TC 0
SN 1534-627
EI 1527-272
J9 Curr Treat Options Oncol
PD NOV 26
PY 2010
VL 11
IS 3-4
BP 141
EP 6
DI 10.1007/s11864-010-0126-0
PG -135
WC Acupuncture Therapy; adverse effects; Humans; Medical Oncology; methods; Meta-Analysis as Topic; Neoplasms; therapy
UT PubMed:21103962
PM 21103962
DA 2010-11-26
ER

PT J
AU O'Regan, D
   Filshie, J
AF O'Regan, David
   Filshie, Jacqueine
TI Acupuncture and cancer.
SO Autonomic neuroscience : basic & clinical
LA English
DT Review
AB Acupuncture has become a popular complementary treatment in oncology,  particularly as patients seek non-pharmacological alternatives to provide symptom  control. A considerable body of evidence suggests that acupuncture modulates  neurological processes to bring about its effects. This basic research is  supported by an increasing number of positive clinical studies of varying  quality. Lower quality studies have hampered the widespread acceptability of  acupuncture, with some deeming the inter-personal skills of the practitioner to  be more powerful than the needle or its equivalent. More recent randomised  control trials (RCTs) have sought to settle this controversy, with mixed results.  The literature was searched to identify, where possible, RCTs involving  acupuncture and various common cancer symptoms. A potential role for acupuncture  was found in the following cancer symptoms: pain, nausea and vomiting,  xerostomia, hot flushes, fatigue, anxiety, depression and insomnia. Acupuncture  is safe with minimal side-effects, and is clinically effective for the management  of these symptoms. Continuing research using validated methodology is essential.  In the interim, health professionals should be open to explore the use of  acupuncture with their cancer patients.
C1 The Royal Marsden Hospital, London and Surrey, UK.
NR 0
TC 0
SN 1872-748
EI 
J9 Auton Neurosci
PD JUL 8
PY 2010
VL 157
IS 1-2
BP 96
EP 100
DI 10.1016/j.autneu.2010.05.001
PG 4
WC Acupuncture Therapy; methods; Anxiety; etiology; Depression; etiology; Fatigue; etiology; Humans; Nausea; etiology; Neoplasms; physiopathology; Pain; etiology; Pain Management; Randomized Controlled Trials as Topic; standards; Vomiting; etiology; Xerostomia; etiology
UT PubMed:20605536
PM 20605536
DA 2010-07-08
ER

PT J
AU Teixeira, MZ
   Guedes, CHFF
   Barreto, PV
   Martins, MA
AF Teixeira, Marcus Z.
   Guedes, Cristina H. F. F.
   Barreto, Patricia V.
   Martins, Milton A.
TI The placebo effect and homeopathy
SO HOMEOPATHY
LA English
DT Article
DE Placebo; Nocebo; Specific effects; Non-specific effects; Expectation; Conditioning; Imaging; qEEG; Homeopathy; Acupuncture
ID irritable-bowel-syndrome; randomized controlled-trials; alternative medicine use; low-back-pain; complementary medicine; parkinsons-disease; cancer-patients; patient expectations; national-survey; united-states
AB Background: Like other forms of medicine, including Complementary and Alternative Medicine (CAM), homeopathy elicits expectations in patients. The physician-patient relationship, personal and comprehensive treatment and lack of adverse effects are elements in creating positive expectations. Other elements may be associated with negative expectations. Methods: We conducted a systematic literature review on placebo and nocebo effects in acupuncture and homeopathy using Medline. Results: Findings on the psychophysiological and neuromediating mechanisms of the placebo-nocebo phenomenon are reviewed. Studies of these effects reveal how expectations and unconscious conditioning can be measured by imaging and EEG methods. They result in significant, non-specific therapeutic effects, which may confuse the evaluation of the specific therapeutic effects treatment, hampering selection of the simillimum. Conclusions: Directions for future research on non-specific therapeutic effects of homeopathy to improve clinical practice and clinical research are discussed. Homeopathy (2010) 99, 119-129.
C1 [Teixeira, Marcus Z.; Guedes, Cristina H. F. F.; Barreto, Patricia V.; Martins, Milton A.] Univ Sao Paulo, Dept Internal Med, Sch Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Teixeira, MZ (corresponding author), Hosp Clin FMUSP, Serv Clin Med Geral, Av Dr Eneas Carvalho Aguiar 155,4 Andar,Bloco 6, BR-05403900 Sao Paulo, Brazil.
EM marcus@homeozulian.med.br
CR Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3
   Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Bausell RB, 2005, EVAL HEALTH PROF, V28, P9, DOI 10.1177/0163278704273081
   Bell IR, 2004, INT J NEUROSCI, V114, P1195, DOI 10.1080/00207450490475724
   Bell IR, 2004, J ALTERN COMPLEM MED, V10, P285, DOI 10.1089/107555304323062275
   Bell IR, 2004, J ALTERN COMPLEM MED, V10, P269, DOI 10.1089/107555304323062266
   Ben Arush M, 2006, J PEDIAT HEMATOL ONC, V28, P141
   Benedetti F, 2007, NEUROSCIENCE, V147, P260, DOI 10.1016/j.neuroscience.2007.02.020
   Benedetti F, 2003, J NEUROSCI, V23, P4315
   Benedetti F, 1999, EUR J NEUROSCI, V11, P625, DOI 10.1046/j.1460-9568.1999.00465.x
   Benedetti F, 1996, PAIN, V64, P535, DOI 10.1016/0304-3959(95)00179-4
   BENEDETTI F, 1995, LANCET, V346, P1231, DOI 10.1016/S0140-6736(95)92938-X
   BIGNAMINI M, 1987, CLINICA TERAPEUTICA, V122, P429
   Brien S, 2004, J ALTERN COMPLEM MED, V10, P499, DOI 10.1089/1075553041323768
   Buettner C, 2006, BREAST CANCER RES TR, V100, P219, DOI 10.1007/s10549-006-9239-3
   Burg MA, 1998, SOUTHERN MED J, V91, P1126, DOI 10.1097/00007611-199812000-00006
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cho HJ, 2005, PSYCHOSOM MED, V67, P301, DOI 10.1097/01.psy.0000156969.76986.e0
   Colloca L, 2004, LANCET NEUROL, V3, P679, DOI 10.1016/S1474-4422(04)00908-1
   de Craen AJM, 1999, J ROY SOC MED, V92, P511, DOI 10.1177/014107689909201005
   de la Fuente-Fernández R, 2004, BIOL PSYCHIAT, V56, P67, DOI 10.1016/j.biopsych.2003.11.019
   de la Fuente-Fernández R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937
   De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7
   Dorn SD, 2007, NEUROGASTROENT MOTIL, V19, P630, DOI 10.1111/j.1365-2982.2007.00937.x
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107
   Fisher P, 2006, HOMEOPATHY, V95, P215, DOI 10.1016/j.homp.2006.07.006
   Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943
   Frei H, 2007, HOMEOPATHY, V96, P35, DOI 10.1016/j.homp.2006.11.004
   Fricchione G, 2005, MED SCI MONITOR, V11, P0
   FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V
   Geers AL, 2006, J BEHAV MED, V29, P171, DOI 10.1007/s10865-005-9040-5
   Goebel MU, 2002, FASEB J, V16, P1869, DOI 10.1096/fj.02-0389com
   HAHNEMANN S, 1991, ORGANON MED, V0, P0
   Hill PB, 2009, VET REC, V164, P364, DOI 10.1136/vr.164.12.364
   Hróbjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x
   Hunsley J, 2007, J CLIN PSYCHOL, V63, P391, DOI 10.1002/jclp.20352
   Ilnyckyj A, 1997, GASTROENTEROLOGY, V112, P1854, DOI 10.1053/gast.1997.v112.pm9178676
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Keltner JR, 2006, J NEUROSCI, V26, P4437, DOI 10.1523/JNEUROSCI.4463-05.2006
   Kirsch I, 1998, PREVENTION TREATMENT, V1, P0, DOI 10.1037/1522-3736.1.1.12A
   Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045
   Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008
   Koyama T, 2005, P NATL ACAD SCI USA, V102, P12950, DOI 10.1073/pnas.0408576102
   Laengler A, 2008, EUR J CANCER, V44, P2233, DOI 10.1016/j.ejca.2008.07.020
   Launso L, 2007, HOMEOPATHY, V96, P233, DOI 10.1016/j.homp.2007.08.011
   Leuchter AF, 2002, AM J PSYCHIAT, V159, P122, DOI 10.1176/appi.ajp.159.1.122
   LEVINE JD, 1979, P NATL ACAD SCI USA, V76, P3528, DOI 10.1073/pnas.76.7.3528
   Lewith GT, 2005, EVID-BASED COMPL ALT, V2, P315, DOI 10.1093/ecam/neh110
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Macedo A, 2008, EUR J PAIN, V12, P68, DOI 10.1016/j.ejpain.2007.03.002
   Marian F, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-52
   Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728
   McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412
   Molassiotis A, 2006, SUPPORT CARE CANCER, V14, P260, DOI 10.1007/s00520-005-0883-7
   Myers SS, 2008, J GEN INTERN MED, V23, P148, DOI 10.1007/s11606-007-0460-5
   OLNESS K, 1992, J DEV BEHAV PEDIATR, V13, P124, DOI 10.1097/00004703-199204000-00008
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176
   Pollo A, 2002, NEUROREPORT, V13, P1383, DOI 10.1097/00001756-200208070-00006
   Price DD, 2001, PAIN, V90, P201, DOI 10.1016/S0304-3959(01)00265-2
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Price DD, 2007, PAIN, V127, P63, DOI 10.1016/j.pain.2006.08.001
   Sauro MD, 2005, J PSYCHOSOM RES, V58, P115, DOI 10.1016/j.jpsychores.2004.07.001
   Su CY, 2004, GASTROENTEROLOGY, V126, P1257, DOI 10.1053/j.gastro.2004.01.024
   Sysko R, 2007, J CLIN PSYCHIAT, V68, P1213, DOI 10.4088/JCP.v68n0807
   Teixeira MZ, 2007, REV ASSOC MED BRAS, V53, P547, DOI 10.1590/S0104-42302007000600026
   Teixeira MZ, 2009, REV ASSOC MED BRAS, V55, P13, DOI 10.1590/S0104-42302009000100008
   TEIXEIRA MZ, 2009, THESIS U SAO PAULO S, V0, P0
   Thompson Trevor D B, 2006, BMC COMPLEMENT ALTERN MED, V6, P37
   Tilburt JC, 2008, BRIT MED J, V337, P0, DOI 10.1136/bmj.a1938
   Träger-Maury S, 2007, B CANCER, V94, P1017
   Van Wassenhoven M, 2004, HOMEOPATHY, V93, P3, DOI 10.1016/j.homp.2003.11.010
   Vase L, 2005, PAIN, V115, P338, DOI 10.1016/j.pain.2005.03.014
   Veeramah EK, 2000, J R SOC PROMO HEALTH, V120, P42, DOI 10.1177/146642400012000117
   Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065
   Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840
   WAMPOLD BE, 2005, J CLIN PSYCHOL, V63, P373
NR 83
TC 15
Z9 18
U1 3
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1475-4916
EI 1476-4245
J9 HOMEOPATHY
JI Homeopathy
PD APR 15
PY 2010
VL 99
IS 2
BP 119
EP 129
DI 10.1016/j.homp.2010.02.001
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 609CC
UT WOS:000278631700006
PM 20471615
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Xie, SX
   Bowman, MA
AF Mao, Jun J.
   Xie, Sharon X.
   Bowman, Marjorie A.
TI UNCOVERING THE EXPECTANCY EFFECT: THE VALIDATION OF THE ACUPUNCTURE EXPECTANCY SCALE
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Article
ID inhibitor-related arthralgia; low-back-pain; patient expectations; controlled-trial; osteoarthritis; placebo; knee; dissociation; metaanalysis; care
AB Purpose circle Research suggests that expectancy may modulate the response to medical interventions, including acupuncture. However, the paucity of validated tools to measure expectancy limits rigorous evaluation. We sought to validate a previously developed Acupuncture Expectancy Scale (AES) as an instrument to measure patients' expected responses to acupuncture. Purpose circle Participants were patients with stage I to III cancers seen in outpatient medical and radiation oncology clinics. They were drawn from three study cohorts that included 404 participants. We examined the reliability, validity, and responsiveness of the AES. Results circle The scores on the AES had internal consistency (Cronbach's alpha coefficient) of 0.95 and test-retest reliability of 0.62 over 4 weeks without acupuncture treatment. Those who had previously used acupuncture had higher AES scores compared to those who were acupuncture nave (12.4 vs 9.5, P = .002). AES scores were higher in those who reported willingness to participate in an acupuncture trial compared to those who did not want to participate in an acupuncture trial (11.5 vs 8.1, P < .001). Patients who enrolled in a pilot trial of acupuncture had higher AES scores than the general outpatient population (13.0 vs 9.8, P = .02), and expectancy increased during the course of acupuncture treatment (13.0 to 16.5, P < .017). Conclusion circle The AES is reliable and valid, and scores appear to increase during or after prior therapy. Incorporation of AES in clinical trials and outcome studies can evaluate the role of expectancy on acupuncture outcomes.
C1 [Mao, Jun J.; Bowman, Marjorie A.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Xie, Sharon X.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Mao, JJ (corresponding author), Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
EM maoj@uphs.upenn.edu
FU National Institutes of Health/National Center for Complementary and Alternative Medicine [K23 AT004112]; American Cancer Society [IRG-78-002-30]; Pennsylvania Department of Aging
CR Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Birch S, 1998, CLIN J PAIN, V14, P248, DOI 10.1097/00002508-199809000-00012
   Bootzin RichardR, 2002, THE SCIENCE OF PLACEBO: TOWARD AN INTERDISCIPLINARY RESEARCH AGENDA, V0, P108
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Coeytaux RR, 2005, HEADACHE, V45, P1113, DOI 10.1111/j.1526-4610.2005.00235.x
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005
   Kirsch I, 1990, CHANGING EXPECTATION, V0, P0
   Kirsch I, 1997, THE PLACEBO EFFECT: AN INTERDISCIPLINARY EXPLORATION, V0, P166
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Linde K, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007587
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Myers SS, 2008, J GEN INTERN MED, V23, P148, DOI 10.1007/s11606-007-0460-5
   Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C
   Reinhold T, 2008, EUR J HEALTH ECON, V9, P209, DOI 10.1007/s10198-007-0062-5
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34
   Streiner D, 1998, HEALTH MEASUREMENT SCALES, V2nd, P0
   Vickers AJ, 2004, HEALTH TECHNOL ASSES, V8, P1
   Walach Harald, 2005, BMC MED RES METHODOL, V5, P26, DOI 10.1186/1471-2288-5-26
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Zubieta JK, 2009, ANN NY ACAD SCI, V1156, P198, DOI 10.1111/j.1749-6632.2009.04424.x
NR 34
TC 56
Z9 63
U1 0
U2 1
PU INNOVISION COMMUNICATIONS
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1078-6791
EI 
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD NOV-DEC 15
PY 2010
VL 16
IS 6
BP 22
EP 27
DI 
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA V28TT
UT WOS:000208703800002
PM 21280459
DA 2026-01-16
ER

PT J
AU Ali, A
   Vitulano, LA
AF Ali, Ather
   Vitulano, Lawrence A
TI A brief report: Yale Research Symposium on Complementary and Integrative
SO The Yale journal of biology and medicine
LA English
DT Journal Article
AB The 2010 Yale Research Symposium on Complementary and Integrative Medicine  highlighted original research in related areas by Yale faculty and provided a  forum to discuss and debate issues of evidence and plausibility. In this brief  report, we describe selected presentations on such diverse foci as nutritional  influences on cancer, acupuncture for low back pain, protein intake's effects on  bone consumption, Chinese herb-derived adjuvant chemotherapy, and the  relationship between anger and cardiac arrhythmia. This symposium demonstrated  that rigorous research methods are being used to study unconventional therapies  and that an integrative medicine approach requires a solid scientific foundation.
C1 Prevention Research Center, Yale University School of Medicine, New Haven, Connecticut 06418, USA. ather.ali@yale.edu
NR 0
TC 0
SN 1551-405
EI 0044-008
J9 Yale J Biol Med
PD OCT 5
PY 2010
VL 83
IS 3
BP 123
EP 5
DI 
PG -118
WC Acupuncture; Complementary Therapies; methods; Congresses as Topic; Humans; Integrative Medicine; methods; Neoplasms; drug therapy
UT PubMed:20885898
PM 20885898
DA 2010-10-05
ER

PT J
AU Dios, PD
   Lestón, JS
AF Dios, Pedro Diz
   Lestón, Juan Seoane
TI Oral cancer pain.
SO Oral oncology
LA English
DT Review
AB Pain may be the initial symptom in oral cancer, and is a common complaint both in  patients awaiting treatment and in those already in treatment. However, little  has been published in the literature on the management of oral cancer pain.  Effective pain control requires a multimodal approach in which pharmacological  management based on the World Health Organization (WHO) analgesic ladder  continues to play an essential role. Although different routes are available for  the administration of analgesics, oral delivery continues to be the principal  route for pain control in the first instance. Interventional approaches include  blockade of a peripheral nerve or of the relevant ganglion, and the use of  central neuraxial blockade. The intraventricular or intrathecal administration of  opioids, with or without local anaesthetics, has been indicated for severe  intractable pain. The development of new treatment modalities provides additional  options, though further clinical research is required. There is no evidence of  the efficacy of non-pharmacological methods such as acupuncture or transcutaneous  nerve stimulation in the management of oral cancer pain. Surgery, radiation  therapy, and chemotherapy have also been suggested, but their results have not  been quantified.
C1 School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain. pedro.diz@usc.es
NR 0
TC 0
SN 1879-059
EI 
J9 Oral Oncol
PD MAR 24
PY 2010
VL 46
IS 6
BP 448
EP 51
DI 10.1016/j.oraloncology.2010.02.017
PG -397
WC Analgesics, Opioid; administration & dosage; Anesthetics, Local; administration & dosage; Carcinoma, Squamous Cell; complications; Early Detection of Cancer; Female; Head and Neck Neoplasms; complications; Humans; Male; Nerve Block; methods; Pain; etiology; Pain Management; Pain Measurement
UT PubMed:20308009
PM 20308009
DA 2010-03-24
ER

PT J
AU Capodice, JL
AF Capodice, Jillian L.
TI Acupuncture in the Oncology Setting: Clinical Trial Update
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
ID palliative medicine; uk association; royal-college; cancer pain; therapy; perspective; management; symptoms
AB Acupuncture, the insertion of sterile needles into acupuncture points of traditional meridians on the body, is a common and effective treatment for a number of supportive care issues in oncology including acute chemotherapy-induced nausea and vomiting. In the Integrative Oncology setting, acupuncture and Traditional Oriental Medicine have become more visible and many oncology clinics, academic health centers and comprehensive cancer centers recommend and administer acupuncture treatment. Continued basic studies on the physiologic mechanisms of acupuncture and recent clinical trials of acupuncture for cancer patients are enhancing our knowledge and informing our guidelines. While debates on methodological problems confronting the study of acupuncture remain, the most recent research demonstrates that acupuncture is safe, tolerable and effective for a range of side effects resulting from conventional cancer treatments.
C1 Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA.
C3 Columbia University
RP Capodice, JL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Urol, 161 Ft Washington Ave,11th Floor, New York, NY 10032 USA.
EM jc2346@columbia.edu
CR Ahn AC, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011907
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Choi JY, 2010, J ASTHMA, V47, P774, DOI 10.3109/02770903.2010.485665
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022
   Hui KKS, 2009, BRAIN RES, V1287, P84, DOI 10.1016/j.brainres.2009.06.061
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lee BC, 2008, J ACUPUNCT MERIDIAN, V1, P13, DOI 10.1016/S2005-2901(09)60002-9
   Luo F, 2008, NEUROCHEM RES, V33, P1950, DOI 10.1007/s11064-008-9692-y
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao Jun James, 2009, J SOC INTEGR ONCOL, V7, P52
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Murotani T, 2010, BRAIN RES, V1306, P62, DOI 10.1016/j.brainres.2009.09.117
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Qin W, 2008, MOL PAIN, V4, P0, DOI 10.1186/1744-8069-4-55
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Raphael J, 2010, PAIN MED, V11, P742, DOI 10.1111/j.1526-4637.2010.00840.x
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   Suzuki M, 2008, J ALTERN COMPLEM MED, V14, P1097, DOI 10.1089/acm.2007.0786
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Wang W, 2007, CHIN J INTEGR MED, V13, P10, DOI 10.1007/s11655-007-0010-3
   Wong Raimond K, 2010, J SOC INTEGR ONCOL, V8, P35
NR 31
TC 4
Z9 8
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD DEC 15
PY 2010
VL 11
IS 3-4
BP 87
EP 94
DI 10.1007/s11864-010-0131-3
PG 8
WC Oncology
SC Oncology
GA 691SJ
UT WOS:000285100800006
PM 21116744
DA 2026-01-16
ER

PT J
AU Ernst, E
   Lee, MS
AF Ernst, Edzard
   Lee, Myeong Soo
TI Acupuncture for palliative and supportive cancer care: a systematic review of
SO Journal of pain and symptom management
LA English
DT Letter
NR 0
TC 0
SN 1873-651
EI 
J9 J Pain Symptom Manage
PD JUL 14
PY 2010
VL 40
IS 1
BP e3
EP 5
DI 10.1016/j.jpainsymman.2010.03.010
PG 1
WC Acupuncture Therapy; Humans; Meta-Analysis as Topic; Neoplasms; complications; Pain; etiology; Pain Management; Palliative Care
UT PubMed:20619198
PM 20619198
DA 2010-07-14
ER

PT J
AU Huh, JE
   Baek, YH
   Lee, MH
   Choi, DY
   Park, DS
   Lee, JD
AF Huh, Jeong-Eun
   Baek, Yong-Hyeon
   Lee, Min-Ho
   Choi, Do-Young
   Park, Dong-Suk
   Lee, Jae-Dong
TI Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice
SO CANCER LETTERS
LA English
DT Article
DE Bee venom; Angiogenesis; Metastasis; VEGF; VEGFR-2
ID recombinant human endostatin; collagen-induced arthritis; cell lung-cancer; growth-factor; in-vivo; acupuncture apipuncture; antiangiogenic therapy; expression; apoptosis; pain
AB Bee venom (BV) treatment is the therapeutic application of honeybee venom (HBV) for treating various diseases in Oriental medicine. In the present work, the authors investigated the functional specificity of BV as an angiogenesis inhibitor using in vitro models and in vivo mouse angiogenesis and lung metastasis models. BV significantly inhibited the viability of Lewis lung carcinoma (LLC) cells but did not affect peripheral blood mononuclear lymphocytes (PBML) cells. BV also inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration and capillary-like tube formation of human umbilical vein endothelial cells (HUVECs). Western blotting analysis showed that BV inhibited Ala and MAPK phosphorylation in LLC cells and HUVECs and down regulated expression of VEGF and VEGFR-2 of LLC cells and HUVECs. Also, BV effectively disrupted VEGF-induced neovascularization in Matrigel plugs in our in vivo angiogenesis assay. When given subcutaneously, BV also significantly suppressed tumor angiogenesis through inhibition of VEGF and VEGFR-2 in LLC model. Mice bearing subcutaneous LLC tumors were treated with 1 mu g/ml or 10 mu g/ml of BV. They showed reductions ranging between 49% and 62% in primary tumor volume and reduction of spontaneous pulmonary metastasis occurrences. Furthermore, BV treatment in the spontaneous lung metastases model after primary tumor excision prolonged their median survival time from 27 to 58 days. These results suggest that the tumor-specific anti-angiogenic activity of BV takes effect during different stages of tumor progression by blocking the tyrosine phosphorylation of VEGFR-2, and validate the application of BV in lung cancer treatment. (C) 2009 Published by Elsevier Ireland Ltd.
C1 [Lee, Min-Ho; Choi, Do-Young; Lee, Jae-Dong] Kyung Hee Univ, Dept Acupuncture & Moxibust, EW Neo Med Ctr, Seoul 134727, South Korea.
   [Baek, Yong-Hyeon; Park, Dong-Suk] Kyung Hee Univ, Dept Acupuncture & Moxibust, Coll Oriental Med, Seoul 130701, South Korea.
   [Huh, Jeong-Eun] Kyung Hee Univ, Oriental Med Res Ctr Bone & Joint Dis, Seoul 134727, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Korea Institute of Oriental Medicine (KIOM)
RP Lee, JD (corresponding author), Kyung Hee Univ, Dept Acupuncture & Moxibust, EW Neo Med Ctr, 149 Sangil Dong, Seoul 134727, South Korea.
EM ljdacu@khu.ac.kr
CR ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Cai KX, 2008, CLIN CANCER RES, V14, P939, DOI 10.1158/1078-0432.CCR-07-1930
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Giaccone G, 2007, CLIN CANCER RES, V13, P1961, DOI 10.1158/1078-0432.CCR-06-2186
   Gorski DH, 1999, CANCER RES, V59, P3374
   Gutierrez M, 2008, CURR OPIN ONCOL, V20, P176, DOI 10.1097/CCO.0b013e3282f4e55e
   HIDER RC, 1988, ENDEAVOUR, V12, P60, DOI 10.1016/0160-9327(88)90082-8
   Hu HY, 2006, J PHARM PHARMACOL, V58, P83, DOI 10.1211/jpp.58.1.0010
   Jang MH, 2003, J PHARMACOL SCI, V91, P95, DOI 10.1254/jphs.91.95
   Jung MH, 2009, CARCINOGENESIS, V30, P655, DOI 10.1093/carcin/bgp039
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim Hyun-Woo, 2004, J VET SCI, V5, P309
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1
   Lariviere WR, 1996, PAIN, V66, P271, DOI 10.1016/0304-3959(96)03075-8
   Lee JD, 2004, AM J CHINESE MED, V32, P361, DOI 10.1142/S0192415X04002016
   Li TS, 2001, EUR J CANCER, V37, P2283, DOI 10.1016/S0959-8049(01)00281-7
   Ling Y, 2007, BIOCHEM BIOPH RES CO, V361, P79, DOI 10.1016/j.bbrc.2007.06.155
   Liu X, 2002, J PHARM PHARMACOL, V54, P1083, DOI 10.1211/002235702320266235
   Maniwa Y, 1998, CHEST, V114, P1668, DOI 10.1378/chest.114.6.1668
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027
   MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220
   PASSANITI A, 1999, LAB INVEST, V267, P519
   Putz T, 2006, CANCER IMMUNOL IMMUN, V55, P1374, DOI 10.1007/s00262-006-0143-9
   Rodriguez SK, 2006, INT J CANCER, V118, P1635, DOI 10.1002/ijc.21545
   Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Suh SJ, 2006, TOXICOL IN VITRO, V20, P1465, DOI 10.1016/j.tiv.2006.06.016
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, PH1344, DOI 10.1152/ajpheart.01246.2008
   TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167
   Thomas JP, 2003, J CLIN ONCOL, V21, P223, DOI 10.1200/JCO.2003.12.120
   VICK JA, 1972, TOXICON, V10, P377, DOI 10.1016/0041-0101(72)90061-X
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Wheatley-Price P, 2008, J THORAC ONCOL, V3, P1173, DOI 10.1097/JTO.0b013e318187220f
   Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, P0
   Xu R, 2003, HEPATOLOGY, V37, P1451, DOI 10.1053/jhep.2003.50244
NR 40
TC 63
Z9 70
U1 1
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 1
PY 2010
VL 292
IS 1
BP 98
EP 110
DI 10.1016/j.canlet.2009.11.013
PG 13
WC Oncology
SC Oncology
GA 597GN
UT WOS:000277744800013
PM 20188461
DA 2026-01-16
ER

PT J
AU Pfister, DG
   Cassileth, BR
   Deng, GE
   Yeung, KS
   Lee, JS
   Garrity, D
   Cronin, A
   Lee, N
   Kraus, D
   Shaha, AR
   Shah, J
   Vickers, AJ
AF Pfister, David G.
   Cassileth, Barrie R.
   Deng, Gary E.
   Yeung, K. Simon
   Lee, Jennifer S.
   Garrity, Donald
   Cronin, Angel
   Lee, Nancy
   Kraus, Dennis
   Shaha, Ashok R.
   Shah, Jatin
   Vickers, Andrew J.
TI Acupuncture for Pain and Dysfunction After Neck Dissection: Results of a Randomized Controlled Trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID quality-of-life; spinal accessory nerve; intensity-modulated radiotherapy; stage nasopharyngeal carcinoma; clinical-trial; postirradiation xerostomia; shoulder; cancer; head; scales
AB Purpose To determine whether acupuncture reduces pain and dysfunction in patients with cancer with a history of neck dissection. The secondary objective is to determine whether acupuncture relieves dry mouth in this population. Patients and Methods Patients at a tertiary cancer center with chronic pain or dysfunction attributed to neck dissection were randomly assigned to weekly acupuncture versus usual care (eg, physical therapy, analgesia, and/or anti-inflammatory drugs, per patient preference or physician recommendation) for 4 weeks. The Constant-Murley score, a composite measure of pain, function, and activities of daily living, was the primary outcome measure. Xerostomia, a secondary end point, was assessed using the Xerostomia Inventory. Results Fifty-eight evaluable patients were accrued and randomly assigned from 2004 to 2007 (28 and 30 patients on acupuncture and control arms, respectively). Constant-Murley scores improved more in the acupuncture group (adjusted difference between groups = 11.2; 95% CI, 3.0 to 19.3; P = .008). Acupuncture produced greater improvement in reported xerostomia (adjusted difference in Xerostomia Inventory = -5.8; 95% CI, -0.9 to -10.7; P = .02). Conclusion Significant reductions in pain, dysfunction, and xerostomia were observed in patients receiving acupuncture versus usual care. Although further study is needed, these data support the potential role of acupuncture in addressing post-neck dissection pain and dysfunction, as well as xerostomia.
C1 Mem Sloan Kettering Canc Ctr, Dept Med, Sect Head & Neck Oncol, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Med, Sect Integrat Med, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Surg Serv, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Pfister, DG (corresponding author), Mem Hosp, 1275 York Ave,Box 188, New York, NY 10065 USA.
EM pfisterd@mskcc.org
FU National Institutes of Health (Bethesda, MD) [CA098792]
CR Andersen SW, 1997, ORAL ONCOL, V33, P146, DOI 10.1016/S0964-1955(96)00058-9
   Bolton JE, 1998, J MANIP PHYSIOL THER, V21, P1
   Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005
   Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339
   Cappiello J, 2005, LARYNGOSCOPE, V115, P259, DOI 10.1097/01.mlg.0000154729.31281.da
   Ceccherelli F, 2001, ACUPUNCTURE ELECTRO, V26, P229, DOI 10.3727/036012901816355938
   Chambers MS, 2007, INT J RADIAT ONCOL, V68, P1102, DOI 10.1016/j.ijrobp.2007.01.019
   Cheng PT, 2000, ANN OTO RHINOL LARYN, V109, P761, DOI 10.1177/000348940010900811
   CONSTANT CR, 1987, CLIN ORTHOP RELAT R, V0, P160
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Erisen L, 2004, HEAD NECK-J SCI SPEC, V26, P967, DOI 10.1002/hed.20095
   Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654
   FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304
   FRYDHOLM M, 1999, J PALLIAT CARE, V15, P20
   Inoue H, 2006, ARCH OTOLARYNGOL, V132, P662, DOI 10.1001/archotol.132.6.662
   Irnich D, 2002, PAIN, V99, P83, DOI 10.1016/S0304-3959(02)00062-3
   Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   JOHNSON JT, 1993, NEW ENGL J MED, V329, P390, DOI 10.1056/NEJM199308053290603
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501
   Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4
   KRAUSE HR, 1992, INT J ORAL MAX SURG, V21, P276
   Kuntz AL, 1999, LARYNGOSCOPE, V109, P1334, DOI 10.1097/00005537-199908000-00030
   Laverick S, 2004, ARCH OTOLARYNGOL, V130, P149, DOI 10.1001/archotol.130.2.149
   LEIPZIG B, 1983, AM J SURG, V146, P526, DOI 10.1016/0002-9610(83)90246-5
   McNeely ML, 2008, CANCER, V113, P214, DOI 10.1002/cncr.23536
   Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x
   Nutting C, 2009, J CLIN ONCOL, V27, P0
   OConnor DA, 1999, ARTHROSCOPY, V15, P836, DOI 10.1053/ar.1999.v15.015083
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   PEETS JM, 1978, NATURE, V273, P675, DOI 10.1038/273675a0
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Robbins KT, 2008, ARCH OTOLARYNGOL, V134, P536, DOI 10.1001/archotol.134.5.536
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   SHONE GR, 1991, J LARYNGOL OTOL, V105, P760, DOI 10.1017/S0022215100117232
   Skutek M, 2000, ARCH ORTHOP TRAUM SU, V120, P432, DOI 10.1007/s004020000133
   SOBOL S, 1985, AM J SURG, V150, P503, DOI 10.1016/0002-9610(85)90164-3
   STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004
   Sun KO, 2001, HONG KONG MEDICAL JOURNAL, V7, P381
   Terrell JE, 2000, LARYNGOSCOPE, V110, P620, DOI 10.1097/00005537-200004000-00016
   Thomson WM, 1999, COMMUNITY DENT HLTH, V16, P12
   van Wilgen CP, 2003, BRIT J ORAL MAX SURG, V41, P7, DOI 10.1016/S0266-4356(02)00288-7
   Vickers A, 2001, BRIT MED J, V323, P1306, DOI 10.1136/bmj.323.7324.1306
   Witt Robert L, 2006, EAR NOSE THROAT J, V85, P540
NR 49
TC 127
Z9 138
U1 2
U2 19
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
BP 2565
EP 2570
DI 10.1200/JCO.2009.26.9860
PG 6
WC Oncology
SC Oncology
GA 598JO
UT WOS:000277832400012
PM 20406930
DA 2026-01-16
ER

PT J
AU Sun, T
   Cui, CB
   Luo, JG
   Zhang, L
   Fu, ZJ
   Song, WG
AF Sun, Tao
   Cui, Cheng-bin
   Luo, Jian-gang
   Zhang, Li
   Fu, Zhi-jian
   Song, Wen-ge
TI [Effect of electroacupuncture on the expression of spinal glial fibrillary acidic
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on the expression of  spinal glial fibrillary acidic protein (GFAP), tumor necrosis factor-alpha  (TNF-alpha) and interleukin-1beta (IL-1beta) in chronic constriction injury (CCI)  rats. METHODS: Seventy-two SD rats were randomized into sham operation (sham),  CCI (model) and EA groups (n = 24/group). The mechanical and thermal pain  thresholds were measured by using Von Frey filaments and radiant-heat irridiation  separately. The immunoactivity of GFAP of spinal dorsal horn (L4-L5) was assessed  by immunohistochemistry, and the expression of spinal TNF-alpha mRNA and IL-1beta  mRNA was detected by real time-PCR. RESULTS: Compared with pre-CCI and sham  group, both mechanical and thermal pain thresholds decreased considerably in rats  with CCI (P < 0.05), and in comparison with model group, those of EA group  increased markedly (P < 0.05). Compared with sham group, GFAP immunoactivity  (mainly in the lamina I-II of the spinal dorsal horn), TNF-alpha mRNA and  IL-1beta mRNA expression in the ipsilateral spinal cord on the CCI side in model  group increased considerably (P < 0.05), while compared with model group, the  expression of GFAP, TNF-alpha mRNA and IL-1beta mRNA in EA group was  down-regulated remarkably (P < 0.05). CONCLUSION: EA can effectively suppress  CCI-induced up-regulation of expression of spinal GFAP, TNF-alpha mRNA and  IL-1beta mRNA, which may contribute to its effect in reducing mechanical  allodynia and thermal hyperalgesia in neuropathic pain rats.
C1 Department of Pain Management, the Affiliated Hospital of Shandong University, Jinan 250021, China. suntao@medmail.com.cn
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAY 13
PY 2010
VL 35
IS 1
BP 12
EP 6
DI 
PG -6
WC Animals; Chronic Disease; therapy; Electroacupuncture; Gene Expression; Glial Fibrillary Acidic Protein; genetics; Humans; Interleukin-1beta; genetics; Male; Neuralgia; genetics; Random Allocation; Rats; Rats, Sprague-Dawley; Spinal Cord; metabolism; Tumor Necrosis Factor-alpha; genetics; Up-Regulation
UT PubMed:20458900
PM 20458900
DA 2010-05-13
ER

PT J
AU Crew, KD
   Capodice, JL
   Greenlee, H
   Brafman, L
   Fuentes, D
   Awad, D
   Tsai, WY
   Hershman, DL
AF Crew, Katherine D.
   Capodice, Jillian L.
   Greenlee, Heather
   Brafman, Lois
   Fuentes, Deborah
   Awad, Danielle
   Tsai, Wei Yann
   Hershman, Dawn L.
TI Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women With Early-Stage Breast Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID postmenopausal women; alternative medicine; chronic pain; tamoxifen therapy; clinical-trials; knee; osteoarthritis; complementary; xerostomia; letrozole
AB Purpose Women with breast cancer (BC) treated with aromatase inhibitors (AIs) may experience joint symptoms that can lead to discontinuation of effective therapy. We examined whether acupuncture improves AI-induced arthralgias in women with early-stage BC. Methods We conducted a randomized, controlled, blinded study comparing true acupuncture (TA) versus sham acupuncture (SA) twice weekly for 6 weeks in postmenopuasal women with BC who had self-reported musculoskeletal pain related to AIs. TA included full body/auricular acupuncture and joint-specific point prescriptions, whereas SA involved superficial needle insertion at nonacupoint locations. Outcome measures included the Brief Pain Inventory-Short Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH) obtained at baseline and at 3 and 6 weeks. Results Of 51 women enrolled, 43 women were randomly assigned and 38 were evaluable. Baseline characteristics were comparable between the two groups. Our primary end point was the difference in mean BPI-SF worst pain scores at 6 weeks, which was lower for TA compared with SA (3.0 v 5.5; P < .001). We also found differences between TA and SA in pain severity (2.6 v 4.5; P = .003) and pain-related interference (2.5 v 4.5; P = .002) at 6 weeks. Similar findings were seen for the WOMAC and M-SACRAH scores. The acupuncture intervention was well-tolerated. Conclusion Women with AI-induced arthralgias treated with TA had significant improvement of joint pain and stiffness, which was not seen with SA. Acupuncture is an effective and well-tolerated strategy for managing this common treatment-related side effect. J Clin Oncol 28: 1154-1160. (C) 2010 by American Society of Clinical Oncology
C1 [Hershman, Dawn L.] Columbia Univ, Dept Epidemiol & Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   Natl Cheng Kung Univ, Dept Stat, Tainan 70101, Taiwan.
C3 Columbia University; National Cheng Kung University
RP Hershman, DL (corresponding author), Columbia Univ, Dept Epidemiol & Biostat, Mailman Sch Publ Hlth, 161 Ft Washington Ave,10-1068, New York, NY 10032 USA.
EM dlh23@columbia.edu
FU Lance Armstrong Young Investigator Award; AVON Products Foundation; Breast Cancer Research Foundation
CR ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Unknown -, 2003, COMM TERM CRIT ADV E, V0, P0
   Baum M, 2002, LANCET, V360, P1520
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Castel LD, 2007, J PAIN SYMPTOM MANAG, V34, P380, DOI 10.1016/j.jpainsymman.2006.12.007
   CHEN C, 2004, XIN ZHONG YI, V36, P46
   CHEN X, 1999, CHINESE ACUPUNCTURE, V0, P134
   CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Dougherty DD, 2008, BEHAV BRAIN RES, V193, P63, DOI 10.1016/j.bbr.2008.04.020
   Ernst E, 2007, AM J CHINESE MED, V35, P21, DOI 10.1142/S0192415X07004588
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.3.CO;2-G
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   KAWAKITA K, 1993, AM J ACUPUNCTURE, V21, P331
   Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X
   Lafferty WE, 2006, AM J MANAG CARE, V12, P397
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   MacPherson H, 2002, J ALTERN COMPLEM MED, V8, P85, DOI 10.1089/107555302753507212
   MATSUMOTO T, 1981, J JPN SOC ACUPUNCT M, V30, P209
   McManus Claire A, 2007, ACUPUNCT MED, V25, P36
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Morales L, 2008, J CLIN ONCOL, V26, P3147, DOI 10.1200/JCO.2007.15.4005
   Pelletier KR, 1999, AM J HEALTH PROMOT, V14, P125, DOI 10.4278/0890-1171-14.2.125
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Qin W, 2008, MOL PAIN, V4, P0, DOI 10.1186/1744-8069-4-55
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Sautner J, 2004, RHEUMATOLOGY, V43, P1409, DOI 10.1093/rheumatology/keh360
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Schnyer RN, 2002, J ALTERN COMPLEM MED, V8, P623, DOI 10.1089/107555302320825147
   SHINOHARA S, 1982, J JPN SOC ACUPUNCT M, V32, P17
   SJOLUND B, 1977, ACTA PHYSIOL SCAND, V100, P382, DOI 10.1111/j.1748-1716.1977.tb05964.x
   Steyer TE, 2002, ALTERN THER HEALTH M, V8, P84
   Takeda W, 1994, ARTHRITIS CARE RES, V7, P118, DOI 10.1002/art.1790070304
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A
   Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   2006, 1900, V4, V0, P79
NR 54
TC 210
Z9 242
U1 2
U2 70
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2010
VL 28
IS 7
BP 1154
EP 1160
DI 10.1200/JCO.2009.23.4708
PG 7
WC Oncology
SC Oncology
GA 560HG
UT WOS:000274892500014
PM 20100963
DA 2026-01-16
ER

PT J
AU Crew, KD
   Capodice, JL
   Greenlee, H
   Brafman, L
   Fuentes, D
   Awad, D
   Yann, Tsai W
   Hershman, DL
AF Crew, Katherine D
   Capodice, Jillian L
   Greenlee, Heather
   Brafman, Lois
   Fuentes, Deborah
   Awad, Danielle
   Yann Tsai, Wei
   Hershman, Dawn L
TI Randomized, blinded, sham-controlled trial of acupuncture for the management of
SO Journal of clinical oncology : official journal of the American Society of
LA English
DT Journal Article
AB PURPOSE Women with breast cancer (BC) treated with aromatase inhibitors (AIs) may  experience joint symptoms that can lead to discontinuation of effective therapy.  We examined whether acupuncture improves AI-induced arthralgias in women with  early-stage BC. METHODS We conducted a randomized, controlled, blinded study  comparing true acupuncture (TA) versus sham acupuncture (SA) twice weekly for 6  weeks in postmenopuasal women with BC who had self-reported musculoskeletal pain  related to AIs. TA included full body/auricular acupuncture and joint-specific  point prescriptions, whereas SA involved superficial needle insertion at  nonacupoint locations. Outcome measures included the Brief Pain Inventory-Short  Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis Index  (WOMAC), and Modified Score for the Assessment of Chronic Rheumatoid Affections  of the Hands (M-SACRAH) obtained at baseline and at 3 and 6 weeks. Results Of 51  women enrolled, 43 women were randomly assigned and 38 were evaluable. Baseline  characteristics were comparable between the two groups. Our primary end point was  the difference in mean BPI-SF worst pain scores at 6 weeks, which was lower for  TA compared with SA (3.0 v 5.5; P < .001). We also found differences between TA  and SA in pain severity (2.6 v 4.5; P = .003) and pain-related interference (2.5  v 4.5; P = .002) at 6 weeks. Similar findings were seen for the WOMAC and  M-SACRAH scores. The acupuncture intervention was well-tolerated. CONCLUSION  Women with AI-induced arthralgias treated with TA had significant improvement of  joint pain and stiffness, which was not seen with SA. Acupuncture is an effective  and well-tolerated strategy for managing this common treatment-related side  effect.
C1 Columbia University, 161 Fort Washington Ave, 10-1068, New York, NY 10032, USA. dlh23@columbia.edu
NR 0
TC 0
SN 1527-775
EI 
J9 J Clin Oncol
PD JAN 27
PY 2010
VL 28
IS 7
BP 1154
EP 60
DI 10.1200/JCO.2009.23.4708
PG -1094
WC Acupuncture Therapy; Adult; Aged; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Female; Humans; Middle Aged; Neoplasm Staging
UT PubMed:20100963
PM 20100963
DA 2010-01-27
ER

PT J
AU Ernst, E
AF Ernst, Edzard
TI Acupuncture.
SO The Lancet. Oncology
LA English
DT Journal Article
C1 Edzard.Ernst@pms.ac.uk
NR 0
TC 0
SN 1474-548
EI 
J9 Lancet Oncol
PD FEB 5
PY 2010
VL 11
IS 1
BP 20
EP 20
DI 10.1016/S1470-2045(09)70399-7
PG 0
WC Acupuncture Therapy; adverse effects; Analgesia; adverse effects; Antineoplastic Agents; adverse effects; Evidence-Based Medicine; Humans; Nausea; chemically induced; Neoplasms; complications; Pain; etiology; Palliative Care; Quackery; Treatment Outcome
UT PubMed:20129129
PM 20129129
DA 2010-02-05
ER

PT J
AU Roscoe, JA
   O'Neill, M
   Jean-Pierre, P
   Heckler, CE
   Kaptchuk, TJ
   Bushunow, P
   Shayne, M
   Huston, A
   Qazi, R
   Smith, B
AF Roscoe, Joseph A.
   O'Neill, Michael
   Jean-Pierre, Pascal
   Heckler, Charles E.
   Kaptchuk, Ted J.
   Bushunow, Peter
   Shayne, Michelle
   Huston, Alissa
   Qazi, Raman
   Smith, Brian
TI An Exploratory Study on the Effects of an Expectancy Manipulation on Chemotherapy-Related Nausea
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Acupressure bands; expectation; chemotherapy; nausea; suggestion; targeted information
ID clinical oncology program; cancer-center community; randomized controlled-trial; placebo; expectations; acupressure; relaxation; predictor; hypnosis; children
AB Context. Previous research has shown that the effectiveness of acupressure bands in reducing chemotherapy-related nausea is related to patients' expectations of efficacy. Objective. To test whether an informational manipulation designed to increase expectation of efficacy regarding acupressure bands would enhance their effectiveness. Methods. We conducted an exploratory, four-arm, randomized clinical trial in breast cancer patients about to begin chemotherapy. All patients received acupressure bands and a relaxation CD. This report focuses on Arm 1(expectancyneutral informational handout and CD) compared with Arm 4 (expectancy-enhancing handout and CD). Randomization was stratified according to the patient's level of certainty that she would have treatment-induced nausea (two levels: high and low). Experience of nausea and use of antiemetics were assessed with a five-day diary. Results. Our expectancy-enhancing manipulation resulted in improved control of nausea in the 26 patients with high nausea expectancies but lessened control of nausea in 27 patients having low nausea expectancies. This interaction effect (between expected nausea and intervention effectiveness) approached statistical significance for our analysis of average nausea (P=0.084) and reached statistical significance for our analysis of peak nausea (P=0.030). Patients receiving the expectancy-enhancing manipulation took fewer antiemetic pills outside the clinic (mean(enhanced) = 12.6; mean(nentral) = 18.5, P=-0.003). Conclusion. This exploratory intervention reduced antiemetic use overall and also reduced nausea in patients who had high levels of expected nausea. Interestingly, it increased nausea in patients who had low expectancies for nausea. Confirmatory research is warranted. J Pain Symptom Manage 2010;40:379-390. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Roscoe, Joseph A.; O'Neill, Michael; Jean-Pierre, Pascal; Heckler, Charles E.; Shayne, Michelle; Huston, Alissa; Qazi, Raman; Smith, Brian] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14642 USA.
   [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Boston, MA USA.
   [Bushunow, Peter] Rochester Gen Hosp, Ctr Canc, Rochester, NY 14621 USA.
C3 University of Rochester; Harvard University; Harvard Medical School; Rochester General Hospital
RP Roscoe, JA (corresponding author), Univ Rochester, James P Wilmot Canc Ctr, 601 Elmwood Ave,Box 704, Rochester, NY 14642 USA.
EM Joseph_Roscoe@urmc.rochester.edu
FU National Cancer Institute [1R21CA118883, 1R25-CA102618-01A1]
CR Alkaissi A, 1999, ACTA ANAESTH SCAND, V43, P270, DOI 10.1034/j.1399-6576.1999.430306.x
   Allan LG, 2002, EVAL HEALTH PROF, V25, P410, DOI 10.1177/0163278702238054
   Unknown -, 2004, COCHRANE DATABASE SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003974.PUB2
   Arakawa S, 1997, CANCER NURS, V20, P342, DOI 10.1097/00002820-199710000-00005
   Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622, DOI 10.1001/jama.287.5.622
   BLAKESLEE S, 2005, MAGAZINE HYPNOSIS HY, V0, P0
   BROADBENT DE, 1977, AM PSYCHOL, V32, P109, DOI 10.1037/0003-066X.32.2.109
   BURISH TG, 1987, J CONSULT CLIN PSYCH, V55, P42, DOI 10.1037/0022-006X.55.1.42
   CAREY MP, 1988, PSYCHOL BULL, V104, P307, DOI 10.1037/0033-2909.104.3.307
   Colagiuri B, 2008, CANCER, V113, P654, DOI 10.1002/cncr.23594
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   DuHamel KN, 1999, ACTA ONCOL, V38, P719
   Ferrara-Love R, 1996, J PERIANESTH NURS, V11, P378
   Flaten MA, 1999, PSYCHOSOM MED, V61, P250, DOI 10.1097/00006842-199903000-00018
   Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124
   Hickok JT, 2003, CANCER, V97, P2880, DOI 10.1002/cncr.11408
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kirsch I, 1999, DISSOCIAT TRAUM MEM, V0, P211
   Kirsch I, 1999, AN PSICOL-SPAIN, V15, P99
   KRASSNER AM, 1994, ATLERNATIVE MED DEFI, V0, P306
   Lotfi-Jam K, 2008, J CLIN ONCOL, V26, P5618, DOI 10.1200/JCO.2007.15.9053
   Marchioro G, 2000, ONCOLOGY-BASEL, V59, P100, DOI 10.1159/000012144
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P237, DOI 10.1007/s00520-001-0329-9
   Montgomery GH, 2002, INT J CLIN EXP HYP, V50, P17, DOI 10.1080/00207140208410088
   Montgomery GH, 2000, BRIT J HEALTH PSYCH, V5, P105, DOI 10.1348/135910700168801
   Neisser U, 1976, COGNITION AND REALITY, V0, P0
   Olver IN, 2005, PSYCHO-ONCOLOGY, V14, P25, DOI 10.1002/pon.804
   Parsons TJ, 1999, INT J OBESITY, V23, P1, DOI 10.3310/hta3030
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Rhodes V A, 1995, CANCER PRACT, V3, P247
   Rhue JW, 1993, HANDBOOK OF CLINICAL HYPNOSIS, V0, P0
   Richardson J, 2007, EUR J CANCER CARE, V16, P402, DOI 10.1111/j.1365-2354.2006.00736.x
   Roscoe JA, 2000, ANN BEHAV MED, V22, P121, DOI 10.1007/BF02895775
   Roscoe JA, 2006, CURR PROB CANCER, V30, P40, DOI 10.1016/j.currproblcancer.2005.12.001
   Roscoe JA, 2004, CANCER-AM CANCER SOC, V101, P2701, DOI 10.1002/cncr.20718
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Roscoe Joseph A, 2006, J SOC INTEGR ONCOL, V4, P16
   Roscoe JA, 2010, SUPPORT CARE CANCER, V18, P869, DOI 10.1007/s00520-009-0723-2
   Roscoe JA, 2009, J PAIN SYMPTOM MANAG, V38, P381, DOI 10.1016/j.jpainsymman.2008.09.006
   Shelke AR, 2008, J PAIN SYMPTOM MANAG, V35, P381, DOI 10.1016/j.jpainsymman.2007.05.008
   Stewart-Williams S, 2004, HEALTH PSYCHOL, V23, P198, DOI 10.1037/0278-6133.23.2.198
   Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324
   WHITE JD, 1983, J PERS SOC PSYCHOL, V45, P538, DOI 10.1037/0022-3514.45.3.538
   WILLIAMS AR, 1994, ANAESTHESIA, V49, P340, DOI 10.1111/j.1365-2044.1994.tb14190.x
   Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041
   ZELTZER LK, 1991, PEDIATRICS, V88, P34
NR 47
TC 33
Z9 37
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD SEP 15
PY 2010
VL 40
IS 3
BP 379
EP 390
DI 10.1016/j.jpainsymman.2009.12.024
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 652TJ
UT WOS:000282032500005
PM 20579837
DA 2026-01-16
ER

PT J
AU Peng, H
   Peng, HD
   Xu, L
   Lao, LX
AF Peng, Hao
   Peng, Hai-Dong
   Xu, Ling
   Lao, Li-Xing
TI [Efficacy of acupuncture in treatment of cancer pain: a systematic review].
SO Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
LA chi
DT Journal Article
AB BACKGROUND: Although acupuncture is a well-established treatment for cancer pain  and its effects have been widely reported in recent two decades, there is still  controversy over whether its efficacy is better than placebo. OBJECTIVE: To  evaluate the efficacy of acupuncture therapy on cancer pain. SEARCH STRATEGY:  Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3,  2008), EMBASE, PubMed, ScienceDirect database, Current Controlled Trials,  Chongqin VIP database and CNKI database were searched, and the search date ended  in June 2008. The authors also hand-searched six Chinese Journals related to the  question. INCLUSION CRITERIA: All randomized controlled trials (RCTs) comparing  acupuncture therapy with placebo, Western drugs, Chinese herbal medicines, or  comparing acupuncture therapy plus drug treatment with drug treatment. DATA  EXTRACTION AND ANALYSIS: Two separate evaluators assessed the quality of the  included reports and extracted the useful information. Disagreements were  resolved through discussion. Meta-analysis of the included trials was done with  RevMan 5.0, and qualitative analysis was employed when meta-analysis was not  appropriate. RESULTS: Seven published RCTs with a total of 634 patients met the  inclusion criteria, and the quality of one of the included trials was high. Due  to flaws in design and reporting, meta-analysis was precluded, and only  qualitative analysis was done on the majority of the reports. The high-quality  trial showed that auricular acupuncture therapy was significantly superior to  placebo in pain alleviation. The other six low-quality trials with non-placebo  showed that acupuncture therapy had some positive effects. CONCLUSION:  Acupuncture is effective for pain relief. However, the poor quality of the  majority of the trials reduces the reliability of the conclusion. More  high-quality RCTs are needed to verify the effects.
C1 Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
NR 0
TC 0
SN 
EI 1672-197
J9 Zhong Xi Yi Jie He Xue Bao
PD JUN 17
PY 2010
VL 8
IS 6
BP 501
EP 9
DI 10.3736/jcim20100601
PG -492
WC Acupuncture Therapy; Humans; Neoplasms; complications; Pain; etiology; Pain Management; methods; Treatment Outcome
UT PubMed:20550871
PM 20550871
DA 2010-06-17
ER

PT J
AU Araújo, LG
   Lima, DMF
   Sampaio, RF
   Pereira, LSM
AF Araujo, Louise G.
   Lima, Debora M. F.
   Sampaio, Rosana F.
   Pereira, Leani S. M.
TI Pain Locus of control scale: adaptation and reliability for elderly
SO BRAZILIAN JOURNAL OF PHYSICAL THERAPY
LA English
DT Article
DE pain control; reliability; cross-cultural adaptation; elderly
ID multidimensional health locus; strategy; efficacy
AB Background: Pain is considered a multidimensional experience and is very common in the elderly. The pain locus of control has become essential to understand how the perceptions, expectations and beliefs are related to individual behavior, attitudes, coping and adherence of the elderly with regards to the health conditions and with the proposed treatment. Studies focused on adaptation and reliability of instruments are necessary for health professionals. Objectives: The present study performed the cross-cultural adaptation of the Pain Locus of Control Scale (C form of Multidimensional Health Locus of Control) for Brazil and assessed its intra and inter-examiner reliability among a sample of 68 elderly individuals with non-oncological pain living in the community. Methods: The cross-cultural adaptation of the scale was performed using the methodology standardized by Beaton et al. (2000)*. Pearson's correlation coefficient (PCC) and the intraclass correlation coefficient (ICC) were used for the statistical analysis (p=0.05). Results: Average age of the subjects was 69.6 +/- 5.5 years; most were women, with low levels of income and education. The average pain duration was 10.2 years and the main clinical diagnosis was osteoarthritis. The reliability of the scale was adequate, with a regular to very strong correlations (PCC = 0.60 to 0.93) and a moderate to nearly perfect ICC (0.60 to 0.93), in mainly the chance locus of control and medical and healthcare professionals locus of control subscales. Conclusion: An adequate reliability and applicability was observed in our sample after adjustments and adaptations of the scale for use in elderly
C1 [Araujo, Louise G.] Ctr Univ Belo Horizonte UniBH, Dept Phys Therapy, Belo Horizonte, MG, Brazil.
   [Sampaio, Rosana F.; Pereira, Leani S. M.] Univ Fed Minas Gerais, Sch Phys Educ Phys Therapy & Occupat Therapy, Dept Phys Therapy, Belo Horizonte, MG, Brazil.
C3 Centro Universitario de Belo Horizonte; Universidade Federal de Minas Gerais
RP Araújo, LG (corresponding author), Rua Perdigao 67,Apto 404, BR-31910190 Belo Horizonte, MG, Brazil.
EM lgara@terra.com.br
CR Andrade Mônica, 2006, REV. PSIQUIATR. RIO GD. SUL, V28, P144, DOI 10.1590/S0101-81082006000200007
   Barry LC, 2005, J GERONTOL A-BIOL, V60, P1569, DOI 10.1093/gerona/60.12.1569
   Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014
   Beissner K, 2009, PHYS THER, V89, P456, DOI 10.2522/ptj.20080163
   BERTOLUCCI PHF, 1994, ARQ NEURO-PSIQUIAT, V52, P1, DOI 10.1590/S0004-282X1994000100001
   Blumstein H, 2005, GERIATRICS, V60, P28
   Coughlin AM, 2000, ARCH PHYS MED REHAB, V81, P739, DOI 10.1016/S0003-9993(00)90103-5
   Cross MJ, 2006, RHEUMATOLOGY, V45, P92, DOI 10.1093/rheumatology/kei114
   Dela Coleta M, 2004, MODELOS PESQUISA MOD, V0, P199
   Geertzen JHB, 2006, DISABIL REHABIL, V28, P363, DOI 10.1080/09638280500287437
   Gibson SJ, 2000, PAIN, V85, P375, DOI 10.1016/S0304-3959(99)00284-5
   Dellaroza MSG, 2007, CAD SAUDE PUBLICA, V23, P1151, DOI 10.1590/S0102-311X2007000500017
   Harris T, 2006, AGE AGEING, V35, P25, DOI 10.1093/ageing/afi216
   Herning Margaret M, 2005, J GERIATR PHYS THER, V28, P34
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Luszczynska A, 2005, J HEALTH PSYCHOL, V10, P633, DOI 10.1177/1359105305055307
   Monsivais D, 2007, PAIN MANAG NURS, V8, P64, DOI 10.1016/j.pmn.2007.03.001
   PAINE P, 1994, PSYCHOL REP, V75, P91, DOI 10.2466/pr0.1994.75.1.91
   Perez RSGM, 2006, DISABIL REHABIL, V28, P339, DOI 10.1080/09638280500287247
   Rodríguez-Rosero Jesús Edilberto, 2002, REV. LATINO-AM. ENFERMAGEM, V10, P179, DOI 10.1590/S0104-11692002000200009
   Rotter J, 2006, TEORIAS DA PERSONALIDADE, V1a, P414
   Salvetti Marina de Góes, 2005, ARCH. CLIN. PSYCHIATRY (SÃO PAULO), V32, P202
   Samwel HJA, 2006, CLIN J PAIN, V22, P245, DOI 10.1097/01.ajp.0000173019.72365.f5
   Santos CC, 2006, ACTA FISIATRICA, V13, P75, DOI 10.11606/issn.2317-0190.v13i2a102586
   SECHREST L, 1972, J CROSS CULT PSYCHOL, V3, P41, DOI 10.1177/002202217200300103
   Tsai YF, 2007, PAIN, V130, P188, DOI 10.1016/j.pain.2007.03.014
   WALLSTON KA, 1994, J PERS ASSESS, V63, P534, DOI 10.1207/s15327752jpa6303_10
   WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107
   Wallston KA, 2005, J HEALTH PSYCHOL, V10, P623, DOI 10.1177/1359105305055304
NR 30
TC 10
Z9 12
U1 0
U2 6
PU ASSOCIACAO BRASILEIRA PESQUISA POS-GRADUACAO FISIOTERAPIA-ABRAPG-FT
PI SAO CARLOS SP
PA ROD WASHINGTON LUIS, KM 235, CAIXA POSTAL 676, SAO CARLOS SP, CEP13565-905, BRAZIL
SN 1413-3555
EI 1809-9246
J9 BRAZ J PHYS THER
JI Braz. J. Phys. Ther.
PD SEP-OCT 15
PY 2010
VL 14
IS 5
BP 438
EP 445
DI 10.1590/S1413-35552010000500014
PG 8
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA 697JW
UT WOS:000285510900014
PM 21180870
DA 2026-01-16
ER

PT J
AU Walters, SJ
AF Walters, Stephen John
TI MASSAGE AND CANCER: PRACTICE GUIDELINES
SO JOURNAL OF THE AUSTRALIAN TRADITIONAL-MEDICINE SOCIETY
LA English
DT Article
DE Massage; Cancer; Guidelines; Evidence-based medicine; Complementary medicine
ID randomized controlled-trial; breast-cancer; complementary therapy; lung-cancer; chemotherapy; acupressure; anxiety; nausea; women; pain
AB Massage is a commonly sought therapy by patients with cancer. Recent research indicates that massage is a valid application for cancer pain, anxiety, nausea and vomitting, lymphedema, and carer support. However, complications such as coagulation disorders, metastatsis to bone, open wounds, and dermatitis require medical management. The evidence supports that massage therapists can offer treatment for patients with cancer with confidence.
RP Walters, SJ (corresponding author), 678 Port Rd, Beverley, SA 5009, Australia.
EM camroc@iinet.net.au
CR Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Campeau Marie-Pierre, 2007, J SOC INTEGR ONCOL, V5, P133, DOI 10.2310/7200.2007.018
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Diaz NM, 2005, ADV ANAT PATHOL, V12, P7, DOI 10.1097/01.pap.0000151267.34438.a1
   Diaz NM, 2004, AM J SURG PATHOL, V28, P1641, DOI 10.1097/00000478-200412000-00014
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Gardani G, 2006, MINERVA MED, V97, P391
   Gardani G, 2007, MINERVA MED, V98, P665
   Gorman Geraldine, 2008, J HOSP PALLIAT NURS, V10, P191
   IMANISHI I, 2009, COMPLEMENT */* EVID, V6, P0
   Iwasaki Mizue, 2005, KURUME MEDICAL JOURNAL, V52, P19, DOI 10.2739/kurumemedj.52.19
   Jane SW, 2009, J PAIN SYMPTOM MANAG, V37, P754, DOI 10.1016/j.jpainsymman.2008.04.021
   Klein Joan, 2004, BR J COMMUNITY NURS, V9, P383
   Kremser T, 2008, BREAST, V17, P387, DOI 10.1016/j.breast.2007.12.006
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   McVicar A J, 2007, COMPLEMENT THER CLIN PRACT, V13, P137, DOI 10.1016/j.ctcp.2006.11.001
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Myers Cynthia D, 2008, J SOC INTEGR ONCOL, V6, P19
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Quattrin R, 2006, J NURS MANAG, V14, P96, DOI 10.1111/j.1365-2934.2006.00557.x
   Russell NC, 2008, J ALTERN COMPLEM MED, V14, P209, DOI 10.1089/acm.2007.7176
   Sagar SM, 2008, CURR ONCOL, V15, P42, DOI 10.3747/co.2008.197
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Warren AG, 2007, ANN PLAS SURG, V59, P464, DOI 10.1097/01.sap.0000257149.42922.7e
   WELLS M, 2007, CANC NURS, V30, P6
   Wells M, 2007, CANCER NURS, V30, P45, DOI 10.1097/00002820-200701000-00008
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987
NR 31
TC 6
Z9 7
U1 2
U2 13
PU AUSTRALIAN TRADITIONAL-MEDICINE SOC LTD
PI MEADOWBANK
PA UNIT 12, 27 BANK ST, PO BOX 1027, MEADOWBANK, NSW 2114, AUSTRALIA
SN 1326-3390
EI 
J9 J AUST TRADIT-MED SO
JI J. Aust. Tradit.-Med. Soc.
PD SEP 15
PY 2010
VL 16
IS 3
BP 141
EP 143
DI 
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 673XH
UT WOS:000283697000002
DA 2026-01-16
ER

PT J
AU Schencking, M
   Kraft, K
AF Schencking, Martin
   Kraft, Karin
TI Inpatient Treatment for Postradical Neck Pain Syndrome by Use of Complementary Medicine
SO FORSCHENDE KOMPLEMENTARMEDIZIN
LA German
DT Article
DE Postradical neck pain syndrome; Thyroid cancer; Neuropathic pain; Allodynia; Naturopathic treatment; Hydrotherapy; Cantharidin blister
ID shoulder dysfunction; cervical plexus; dissection; cancer; age
AB Inpatient Treatment for Postradical Neck Pain Syndrome by Use of Complementary Medicine Introduction: The standard treatment of papillary thyroid cancer with a diameter >1 cm is thyroidectomy combined with a modified neck-dissection of the central (perithyroideal, prelaryngeal and tracheo-esophageal) lymph nodes and a consecutive radiation. Frequently, postoperative pain syndromes occur after this procedure. The so-called 'postradical neck pain syndrome' (PRNS) is a combination of cervical neuropathic pain, constricted and painful mobility of the shoulder region(s) including inhibited abduction capacity of the shoulder joint and a scapula alata. PRNS is often resistant to conventional therapy such as analgesics and physiotherapy. Case Report: A 56-year-old female inpatient, suffering from a severe PRNS after thyroidectomy and neck dissection due to papillary thyroid cancer for the past 2 years, was treated with a combination of hydrotherapy according to Kneipp, conventional physiotherapy, acupuncture and cantharidin blisters in order to reduce neuropathic pain, increase the range of cervical mobility and improve parameters of health-related quality of life (based on SF-36). Results: Within 4 weeks of combined treatment, the left-cervical neuropathic pain was improved remarkably, and the range of the cervical mobility was increased sufficiently. In addition, the SF-36 scales 'pain' and 'common well-being' were improved to a clinically relevant extent. The multi-modular treatment was well tolerated. Conclusions: In PRNS, a combination of several methods of complementary medicine may be an effective and well tolerated alternative to conventional treatment. Further clinical studies are required to confirm the results.
C1 [Schencking, Martin] Kneippsche Kliniken, Bad Worishofen, Germany.
   [Kraft, Karin] Univ Rostock, Klin & Poliklin Innere Med, Lehrstuhl Nat Heilkunde, D-2500 Rostock 1, Germany.
C3 University of Rostock
RP Schencking, M (corresponding author), Rheinstr 77A, D-56235 Ransbach Baumbach, Germany.
EM naturedoc@web.de
CR Agha-Mir-Salim P, 2002, HNO, V50, P544, DOI 10.1007/s00106-001-0587-3
   Bullinger M, 1996, REHABILITATION (STUTTG), V35, P0
   Campos A, 1996, ACTA OTORRINOLARINGOL ESP, V47, P387
   Chen AY, 2009, CANCER-AM CANCER SOC, V115, P3801, DOI 10.1002/cncr.24416
   Cheng PT, 2000, ANN OTO RHINOL LARYN, V109, P761, DOI 10.1177/000348940010900811
   Cook MB, 2009, CANCER EPIDEM BIOMAR, V18, P1174, DOI 10.1158/1055-9965.EPI-08-1118
   Dilber M, 2007, EUR ARCH OTO-RHINO-L, V264, P1333, DOI 10.1007/s00405-007-0357-2
   Dorsher PT, 2008, J ALTERN COMPLEM MED, V14, P353, DOI 10.1089/acm.2007.0810
   Fleming Sara, 2007, BMC COMPLEMENT ALTERN MED, V7, P15, DOI 10.1186/1472-6882-7-15
   Kilfoy BA, 2009, CANCER EPIDEM BIOMAR, V18, P1092, DOI 10.1158/1055-9965.EPI-08-0976
   Leenhardt L, 2009, J RADIOL, V90, P354, DOI 10.1016/S0221-0363(09)72520-X
   Manxhuka-Kerliu S, 2009, BOSNIAN J BASIC MED, V9, P111, DOI 10.17305/bjbms.2009.2829
   MATCJKA R, 2000, AUSLEITENDE THERAPIE, V0, P123
   McNeely ML, 2008, CANCER, V113, P214, DOI 10.1002/cncr.23536
   Orhan KS, 2007, J LARYNGOL OTOL, V121, P44, DOI 10.1017/S0022215106002052
   PFISTER D, 2008, J CLIN ONCOL S, V0, P0
   PREISS J, 2006, ONKOLOGIE INTEGRATIV, V1, P590
   SCHENCKING M, 2009, NOTFALL HAUSARZTMED, V35, P352
   Schencking M, 2008, FORSCH KOMPLEMENTMED, V15, P273, DOI 10.1159/000159386
   Schencking M, 2009, FORSCH KOMPLEMENTMED, V16, P117, DOI 10.1159/000210561
   SIMONS DG, 2002, HDB MUSKEL TRIGGERPU, V2, P45
   Sist T, 1999, J PAIN SYMPTOM MANAG, V18, P95, DOI 10.1016/S0885-3924(99)00054-8
   Wittekindt C, 2006, LARYNGOSCOPE, V116, P1168, DOI 10.1097/01.mlg.0000217797.05523.75
NR 23
TC 0
Z9 0
U1 1
U2 18
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1021-7096
EI 
J9 FORSCH KOMPLEMENTMED
JI Forsch. Komplement.med.
PD JUN 15
PY 2010
VL 17
IS 2
BP 81
EP 86
DI 10.1159/000287920
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 594YT
UT WOS:000277578300005
PM 20484915
DA 2026-01-16
ER

PT J
AU Lee, MS
   Kang, JW
   Ernst, E
AF Lee, Myeong Soo
   Kang, Jung Won
   Ernst, Edzard
TI Does moxibustion work? An overview of systematic reviews.
SO BMC research notes
LA English
DT Journal Article
AB BACKGROUND: Several systematic reviews (SRs) have assessed the effectiveness of  moxibustion for a range of conditions, often with contradictory conclusions. Our  aim was to provide a critical evaluation and summary of these data. METHODS:  Electronic searches were conducted to locate all SRs of moxibustion for any  condition. Data were extracted by two authors according to predefined criteria.  RESULTS: Ten SRs met our inclusion criteria, which related to the following  conditions: cancer, ulcerative colitis, stroke rehabilitation, constipation,  hypertension, pain conditions and breech presentation. Their conclusions were  contradictory in several instances. Relatively clear evidence emerged to suggest  that moxibustion is effective for breech presentation. CONCLUSIONS: Based on  evidence from the currently available SRs, the effectiveness of moxibustion has  been demonstrated for several conditions; however, due to the poor quality of the  primary studies, there remains considerable uncertainty.
C1 Policy Division, Korea Institute of Oriental Medicine, Daejeon, South Korea. drmslee@gmail.com.
NR 0
TC 0
SN 1756-050
EI 
J9 BMC Res Notes
PD NOV 9
PY 2010
VL 3
IS 
BP 284
EP 284
DI 10.1186/1756-0500-3-284
PG 0
UT PubMed:21054851
PM 21054851
DA 2010-11-09
ER

PT J
AU Lu, WD
   Posner, MR
   Wayne, P
   Rosenthal, DS
   Haddad, RI
AF Lu, Weidong
   Posner, Marshall R.
   Wayne, Peter
   Rosenthal, David S.
   Haddad, Robert I.
TI Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer: A Case Series Report
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; chemoradiation therapy; radiation therapy; head and neck cancer; dysphagia; percutaneous endoscopic gastrostomy (PEG) tube
ID locally advanced head; quality-of-life; radiation-induced xerostomia; organ preservation; intraarterial chemoradiation; induction chemotherapy; oropharyngeal cancer; radiotherapy; chemoradiotherapy; impact
AB Background: Dysphagia is a common side effect following chemoradiation therapy (CRT) in patients with head and neck cancer (HNC). Methods: In this retrospective case series, 10 patients with HNC were treated with acupuncture for radiation-induced dysphagia and xerostomia. All patients were diagnosed with stage III/IV squamous cell carcinoma. In all, 7 of 10 patients were percutaneous endoscopic gastrostomy (PEG) tube dependent when they began acupuncture. Manual acupuncture and electroacupuncture were used once a week. Results: A total of 9 of 10 patients reported various degrees of subjective improvement in swallowing functions, xerostomia, pain, and fatigue levels. Overall, 6 (86%) of 7 PEG tube-dependent patients had their feeding tubes removed after acupuncture, with a median duration of 114 days (range 49 to 368 days) post CRT. One typical case is described in detail. Conclusions: A relatively short PEG tube duration and reduced symptom severity following CRT were observed in these patients. Formal clinical trials are required to determine the causality of the observations.
C1 [Lu, Weidong] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA.
   [Lu, Weidong; Wayne, Peter] Harvard Univ, Sch Med, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School
RP Lu, WD (corresponding author), Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, 44 Binney St, Boston, MA 02115 USA.
EM weidong_lu@dfci.harvard.edu
FU National Center for Complementary and Alternative Medicine (NCCAM) [1K01AT004415-01]
CR Citrin D, 2009, INT J RADIAT ONCOL, V74, P1040, DOI 10.1016/j.ijrobp.2008.09.053
   Connor NP, 2006, INT J RADIAT ONCOL, V65, P1051, DOI 10.1016/j.ijrobp.2006.01.054
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302
   Duncan GG, 2005, HEAD NECK-J SCI SPEC, V27, P421, DOI 10.1002/hed.20162
   Garcia MK, 2009, HEAD NECK-J SCI SPEC, V31, P1360, DOI 10.1002/hed.21110
   Goguen LA, 2006, OTOLARYNG HEAD NECK, V134, P916, DOI 10.1016/j.otohns.2006.02.001
   Guadagnolo BA, 2005, AM J CLIN ONCOL-CANC, V28, P371, DOI 10.1097/01.coc.0000162423.13431.8d
   Haddad R, 2009, CANCER, V115, P4514, DOI 10.1002/cncr.24525
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471
   Lazarus CL, 2000, J SPEECH LANG HEAR R, V43, P1011, DOI 10.1044/jslhr.4304.1011
   Lorch JH, 2008, HEMATOL ONCOL CLIN N, V22, P1155, DOI 10.1016/j.hoc.2008.08.004
   Machtay M, 2002, J CLIN ONCOL, V20, P3964, DOI 10.1200/JCO.2002.11.026
   Murry T, 1998, HEAD NECK-J SCI SPEC, V20, P31, DOI 10.1002/(SICI)1097-0347(199801)20:1<31::AID-HED6>3.0.CO;2-4
   Nguyen NP, 2006, SURG ONCOL, V15, P199, DOI 10.1016/j.suronc.2006.12.002
   Nguyen NP, 2007, ORAL ONCOL, V43, P352, DOI 10.1016/j.oraloncology.2006.04.002
   Nguyen NP, 2002, CANCER-AM CANCER SOC, V94, P1131, DOI 10.1002/cncr.10257
   Nguyen NP, 2004, ANN ONCOL, V15, P383, DOI 10.1093/annonc/mdh101
   Nowicki NC, 2003, MED ACUPUNCTURE, V14, P17
   Pauloski BR, 2000, HEAD NECK-J SCI SPEC, V22, P120, DOI 10.1002/(SICI)1097-0347(200003)22:2<120::AID-HED3>3.3.CO;2-L
   PAULOSKI BR, 1994, HEAD NECK-J SCI SPEC, V16, P313, DOI 10.1002/hed.2880160404
   Peterman A, 2001, J NATL CANCER INST MONOGR, V0, P45
   Seki T, 2003, J AM GERIATR SOC, V51, P726
   Shen H, 1996, ZHEJIANG J TRADIT CH, V31, P561
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   van den Broek GB, 2006, RADIOTHER ONCOL, V81, P143, DOI 10.1016/j.radonc.2006.09.002
   Vokes EE, 2003, J CLIN ONCOL, V21, P320, DOI 10.1200/JCO.2003.06.006
   Wang Li-ping, 2006, ZHONGGUO ZHEN JIU, V26, P141
   Wiggenraad RGJ, 2007, CLIN OTOLARYNGOL, V32, P384, DOI 10.1111/j.1749-4486.2007.01533.x
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   Xie Y, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006076.pub2
   Zhang W, 2002, ZHONGUO ZHEN JIU, V22, P405
   Zheng P, 2002, CHIN J INFORM TRADIT, V9, P63
   Zhou H, 2006, CHIN J REHABIL THEOR, V12, P58
NR 39
TC 18
Z9 22
U1 1
U2 23
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2010
VL 9
IS 3
BP 284
EP 290
DI 10.1177/1534735410378856
PG 7
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 653LD
UT WOS:000282091900007
PM 20713374
DA 2026-01-16
ER

PT J
AU Avis, NE
   Coeytaux, RR
AF Avis, Nancy E.
   Coeytaux, Remy R.
TI The role of acupuncture in treating menopausal hot flashes
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Editorial Material
ID estrogen plus progestin; middle-aged women; quality-of-life; low-back-pain; postmenopausal women; breast-cancer; patient expectations; applied relaxation; hormone-therapy; symptoms
C1 [Avis, Nancy E.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Dept Social Sci & Hlth Policy, Winston Salem, NC 27109 USA.
   [Coeytaux, Remy R.] Duke Univ, Sch Med, Dept Community & Family Med, Durham, NC USA.
C3 Wake Forest University; Duke University
RP Avis, NE (corresponding author), Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Dept Social Sci & Hlth Policy, Winston Salem, NC 27109 USA.
CR Avis N E, 1997, WOMENS HEALTH, V3, P103
   Avis NE, 2008, MENOPAUSE, V15, P1070, DOI 10.1097/gme.0b013e31816d5b03
   Avis NE, 2003, MED CARE, V41, P1262, DOI 10.1097/01.MLR.0000093479.39115.AF
   Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4
   Birch S, 2003, CLIN ACUPUNCTURE ORI, V4, P59, DOI 10.1016/S1461-1449(03)00025-2
   Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad
   Bosworth HB, 2005, J BEHAV MED, V28, P105, DOI 10.1007/s10865-005-2721-2
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cho SH, 2009, MENOPAUSE, V16, P1065, DOI 10.1097/gme.0b013e3181a48abd
   DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Fuh JL, 2003, QUAL LIFE RES, V12, P53, DOI 10.1023/A:1022074602928
   Guthrie JR, 2003, CLIMACTERIC, V6, P112, DOI 10.1080/713605371
   Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100
   JOHANNES CB, 1994, AM J EPIDEMIOL, V140, P439, DOI 10.1093/oxfordjournals.aje.a117266
   Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005
   Kerr EA, 2005, ANN INTERN MED, V142, P154, DOI 10.7326/0003-4819-142-2-200501180-00021
   Kessel B, 2004, ENDOCRIN METAB CLIN, V33, P717, DOI 10.1016/j.ecl.2004.07.004
   Kim KH, 2010, MENOPAUSE, V17, P269, DOI 10.1097/gme.0b013e3181bfac3b
   KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52
   Kumari M, 2005, J CLIN EPIDEMIOL, V58, P719, DOI 10.1016/j.jclinepi.2004.09.016
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Nedrow A, 2006, ARCH INTERN MED, V166, P1453, DOI 10.1001/archinte.166.14.1453
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459
   Nir Y, 2007, MATURITAS, V56, P383, DOI 10.1016/j.maturitas.2006.11.001
   PIANSMITH MCM, 2001, ACUPUNCTURE TREATMEN, V0, P8
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   Utian Wulf H, 2005, HEALTH QUAL LIFE OUTCOMES, V3, P47, DOI 10.1186/1477-7525-3-47
   Vincent A, 2007, MENOPAUSE, V14, P45, DOI 10.1097/01.gme.0000227854.27603.7d
   Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673
   Wyon Y, 2004, CLIMACTERIC, V7, P153, DOI 10.1080/13697130410001713814
   Zaborowska E, 2007, CLIMACTERIC, V10, P38, DOI 10.1080/13697130601165059
NR 37
TC 0
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD MAR 15
PY 2010
VL 17
IS 2
BP 228
EP 230
DI 10.1097/gme.0b013e3181d298e4
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 567YN
UT WOS:000275485200003
PM 20142787
DA 2026-01-16
ER

PT J
AU Dean-Clower, E
   Doherty-Gilman, AM
   Keshaviah, A
   Baker, F
   Kaw, C
   Lu, WD
   Manola, J
   Penson, RT
   Matulonis, UA
   Rosenthal, DS
AF Dean-Clower, Elizabeth
   Doherty-Gilman, Anne M.
   Keshaviah, Aparna
   Baker, Frank
   Kaw, Chiewkwei
   Lu, Weidong
   Manola, Judith
   Penson, Richard T.
   Matulonis, Ursula A.
   Rosenthal, David S.
TI Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; palliative care; symptom management; ovarian cancer; breast cancer
ID alternative medicine use; breast-cancer; short-form; complementary; pain; electroacupuncture; prevalence; attitudes; survivors; profile
AB Background. Acupuncture is underutilized as an adjunct cancer therapy. The main study objectives were to determine the feasibility of administering acupuncture as palliative therapy to patients with advanced ovarian or breast cancer and to assess the effect on symptoms and quality of life (QOL). Methods. This study was a pilot, single-armed prospective clinical trial for patients with advanced cancer to receive 12 acupuncture sessions over 8 weeks with follow-up at weeks 9 and 12. Ambulatory patients with advanced ovarian or breast cancer were enrolled to receive treatments at an outpatient academic oncology center. Symptom severity was measured before and after each acupuncture session. A composite QOL assessment tool, consisting of validated instruments, was completed at 5 time points. Results. Forty patients enrolled in the study. Twenty-eight patients (70%; 95% confidence interval [CI] = 53%-83%) completed 4 weeks of treatment, and 26 patients (65%; 95% CI = 48%-79%) completed 8 weeks. Eight patients (20%) withdrew before receiving acupuncture, and 6 patients (15%) discontinued treatment early because of disease progression or scheduling demands. Among all 32 assessed patients, there was self-reported improvement immediately post-treatment in anxiety, fatigue, pain, and depression and significant improvement over time for patients with anxiety (P=.001) and depression (P=.02). Among patients experiencing baseline symptoms, there was improvement in anxiety (P=.001), fatigue (P=.0002), pain (P=.0002), and depression (P=.003). QOL measures of pain severity and interference, physical and psychological distress, life satisfaction, and mood states showed improved scores during treatment, with sustained benefit at 12 weeks. Conclusions. This pilot study demonstrates that an 8-week outpatient acupuncture course is feasible for advanced cancer patients and produces a measurable benefit that should be evaluated in controlled trials.
C1 [Rosenthal, David S.] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA.
   [Baker, Frank] New York Med Coll, Ctr Med Outcomes Res, Sch Hlth Sci & Practice, Valhalla, NY 10595 USA.
   [Kaw, Chiewkwei] Amer Canc Soc, Atlanta, GA 30329 USA.
   [Keshaviah, Aparna; Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Dean-Clower, Elizabeth; Lu, Weidong; Penson, Richard T.; Matulonis, Ursula A.; Rosenthal, David S.] Harvard Univ, Sch Med, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; New York Medical College; American Cancer Society; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Harvard University; Harvard Medical School
RP Rosenthal, DS (corresponding author), Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, 44 Binney St, Boston, MA 02115 USA.
EM drose@uhs.harvard.edu
FU National Center for Complementary and Alternative Medicine (NCCAM) [5 R21 AT01010-02]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Armstrong T, 2006, J PAIN SYMPTOM MANAG, V32, P148, DOI 10.1016/j.jpainsymman.2006.02.015
   BAKER F, 1991, SOC SCI MED, V32, P697, DOI 10.1016/0277-9536(91)90149-7
   Baker F, 2002, PSYCHO-ONCOLOGY, V11, P273, DOI 10.1002/pon.564
   Baker F, 2007, J PSYCHOSOC ONCOL, V25, P1, DOI 10.1300/J077v25n02_01
   Baker Frank, 1992, JOURNAL OF PSYCHOSOCIAL ONCOLOGY, V10, P75
   Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Cui Y, 2004, BREAST CANCER RES TR, V85, P263, DOI 10.1023/B:BREA.0000025422.26148.8d
   CURRAN SL, 1995, PSYCHOL ASSESSMENT, V7, P80, DOI 10.1037/1040-3590.7.1.80
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434
   du Bois A, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi961
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Faily J, 2007, SUPPORT CARE CANCER, V15, P1003, DOI 10.1007/s00520-007-0294-z
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Gejervall AL, 2005, HUM REPROD, V20, P728, DOI 10.1093/humrep/deh665
   Hann D M, 2005, INTEGR CANCER THER, V4, P294, DOI 10.1177/1534735405282109
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Lafferty WE, 2004, CANCER-AM CANCER SOC, V100, P1522, DOI 10.1002/cncr.20105
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   Mao JJ, 2007, COMPLEMENT THER MED, V15, P21, DOI 10.1016/j.ctim.2006.07.006
   McNair DM, 1971, EITS MANUAL PROFILE, V0, P0
   Milden SP, 2004, BEHAV MED, V30, P73, DOI 10.3200/BMED.30.2.73-84
   Molassiotis A, 2005, COMPLEMENT THER MED, V13, P251, DOI 10.1016/j.ctim.2005.07.002
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Penson RT, 2006, INT J GYNECOL OBSTET, V95, PS247, DOI 10.1016/S0020-7292(06)60040-4
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H
   SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stein KD, 2003, J PAIN SYMPTOM MANAG, V26, P975, DOI 10.1016/S0885-3924(03)00321-X
   Tasaki K, 2002, PSYCHO-ONCOL, V11, P212, DOI 10.1002/pon.552
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vickers AJ, 2001, LANCET ONCOL, V2, P226, DOI 10.1016/S1470-2045(00)00293-X
   Wahner-Roedler DL, 2006, EVID-BASED COMPL ALT, V3, P495, DOI 10.1093/ecam/nel036
   Wang SM, 2005, ANESTH ANALG, V101, P666, DOI 10.1213/01.ANE.0000175212.17642.45
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Yates JS, 2005, SUPPORT CARE CANCER, V13, P806, DOI 10.1007/s00520-004-0770-7
NR 45
TC 58
Z9 71
U1 1
U2 30
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2010
VL 9
IS 2
BP 158
EP 167
DI 10.1177/1534735409360666
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 617HW
UT WOS:000279272600004
PM 20483875
DA 2026-01-16
ER

PT J
AU Schencking, M
   Kraft, K
AF Schencking, Martin
   Kraft, Karin
TI [Inpatient treatment for postradical neck pain syndrome by use of complementary
SO Forschende Komplementarmedizin (2006)
LA ger
DT Journal Article
AB INTRODUCTION: The standard treatment of papillary thyroid cancer with a diameter  >1 cm is thyroidectomy combined with a modified neck-dissection of the central  (perithyroideal, prelaryngeal and tracheo-esophageal) lymph nodes and a  consecutive radiation. Frequently, postoperative pain syndromes occur after this  procedure. The so-called 'postradical neck pain syndrome' (PRNS) is a combination  of cervical neuropathic pain, constricted and painful mobility of the shoulder  region(s) including inhibited abduction capacity of the shoulder joint and a  scapula alata. PRNS is often resistant to conventional therapy such as analgesics  and physiotherapy. CASE REPORT: A 56-year-old female inpatient, suffering from a  severe PRNS after thyroidectomy and neck dissection due to papillary thyroid  cancer for the past 2 years, was treated with a combination of hydrotherapy  according to Kneipp, conventional physiotherapy, acupuncture and cantharidin  blisters in order to reduce neuropathic pain, increase the range of cervical  mobility and improve parameters of health-related quality of life (based on  SF-36). RESULTS: Within 4 weeks of combined treatment, the left-cervical  neuropathic pain was improved remarkably, and the range of the cervical mobility  was increased sufficiently. In addition, the SF-36 scales 'pain' and 'common  well-being' were improved to a clinically relevant extent. The multi-modular  treatment was well tolerated. CONCLUSIONS: In PRNS, a combination of several  methods of complementary medicine may be an effective and well tolerated  alternative to conventional treatment. Further clinical studies are required to  confirm the results.
C1 Kneippsche Kliniken, Bad Wörishofen, Germany. naturedoc@web.de
NR 0
TC 0
SN 1661-412
EI 
J9 Forsch Komplementmed
PD MAY 21
PY 2010
VL 17
IS 2
BP 81
EP 6
DI 10.1159/000287920
PG -75
WC Acupuncture; Adenocarcinoma, Papillary; surgery; Administration, Cutaneous; Cantharidin; administration & dosage; Chronic Disease; Combined Modality Therapy; Female; Hospitalization; Humans; Hydrotherapy; Middle Aged; Naturopathy; Neck Dissection; Neuralgia; therapy; Pain, Postoperative; therapy; Physical Therapy Modalities; Thyroid Neoplasms; surgery; Thyroidectomy
UT PubMed:20484915
PM 20484915
DA 2010-05-21
ER

PT J
AU Tuck, CM
AF Tuck, Claire M
TI A 54-year-old woman with degenerative back pain.
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
AB Back pain is a common symptom: up to 70% of UK adults experience this symptom by  the age of 60 and most have moderate to severe pain. Back pain accounted for 12%  of consultations to traditional acupuncturists in 2001 and is one of the most  common reasons for consultation with an acupuncturist. This case report concerns  a 54-year-old woman with metastatic breast cancer and degenerative lower back  pain, which remained painful despite intensive pharmaceutical management and  facet joint injection and was ultimately successfully managed with two 30 min  acupuncture treatments 2 weeks apart, using eight points on the BL meridians.  Acupuncture treatment using tender points was later trialled for neuropathic pain  secondary to local recurrence in her mastectomy scar, however this was  unsuccessful and inpatient hospice admission for further intensive pharmaceutical  management was required.
C1 Strathcarron Hospice, Randolph Hill, Denny, Stirlingshire FK6 5HJ, UK. clairetuck@nhs.net
NR 0
TC 0
SN 
EI 0964-528
J9 Acupunct Med
PD MAR 31
PY 2010
VL 28
IS 1
BP 46
EP 8
DI 10.1136/aim.2009.000687
PG -38
WC Acupuncture Analgesia; methods; Breast Neoplasms; complications; Chronic Disease; Female; Humans; Low Back Pain; etiology; Mastectomy; adverse effects; Meridians; Middle Aged; Pain, Intractable; etiology
UT PubMed:20351378
PM 20351378
DA 2010-03-31
ER

PT J
AU Henss, H
   Münstedt, K
   Jückstock, J
   Reinert, E
   Hübner, J
AF Henss, H.
   Muenstedt, K.
   Jueckstock, J.
   Reinert, E.
   Huebner, J.
TI Supportive measures of complementary medicine
SO ONKOLOGE
LA German
DT Article
DE Supportive care; Complementary therapy; Acupuncture; Phytotherapy; Mind-body techniques
ID chemotherapy-induced nausea; controlled clinical-trial; irritable-bowel-syndrome; breast-cancer patients; alternative medicine; double-blind; anticipatory nausea; acupuncture; prevention; pain
AB When controlling symptoms in malignant diseases, complementary therapies can make important contributions. This is demonstrated in several important and/or frequent symptoms in cancer patients. Complementary therapies should supplement but not replace established treatments and can be useful, especially where no other established procedures are available. Treatments involve herbal applications as well as acupuncture and so-called mind-body techniques. As information on tumor patients is sometimes insufficient, extrapolation from experiences with other diseases may be helpful, at least as far as side-effects are concerned. Possible drug interactions must be kept in mind especially with herbal treatments.
C1 [Henss, H.; Reinert, E.] Univ Klinikum Freiburg, Tumorzentrum Ludwig Heilmeyer CCCF, D-79106 Freiburg, Germany.
   Klinikum Justus Liebig Univ Giessen, Geburtshilfe & Gynakol Abt, Giessen, Germany.
   [Jueckstock, J.] Klinikum Ludwig Maximilians Univ Munchen, Frauenklin Innenstadt, Munich, Germany.
   [Huebner, J.] UCT Univ Klinikum Frankfurt, Palliat Med & Komplementare Onkol, Frankfurt, Germany.
C3 University of Freiburg; Justus Liebig University Giessen; University of Munich
RP Henss, H (corresponding author), Univ Klinikum Freiburg, Tumorzentrum Ludwig Heilmeyer CCCF, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM hartmut.henss@uniklinik-freiburg.de
CR Aapro MS, 2005, SUPPORT CARE CANCER, V13, P117, DOI 10.1007/s00520-004-0745-8
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015
   Bardy J, 2008, J CLIN NURS, V17, P2604, DOI 10.1111/j.1365-2702.2008.02304.x
   Bent S, 2006, AM J MED, V119, P1005, DOI 10.1016/j.amjmed.2006.02.026
   Bierbach E, 2009, NATURHEILPRAXIS HEUT, V0, P0
   Bruera E, 2003, J CLIN ONCOL, V21, P129, DOI 10.1200/JCO.2003.01.101
   Carrozza MC, 2007, IEEE-ASME T MECH, V12, P1, DOI 10.1109/TMECH.2006.886250
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Chang FY, 2009, J CHIN MED ASSOC, V72, P294, DOI 10.1016/S1726-4901(09)70375-2
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Colomer R, 2007, BRIT J NUTR, V97, P823, DOI 10.1017/S000711450765795X
   Crockett Sara L, 2007, PHARM UNSERER ZEIT, V36, P381, DOI 10.1002/pauz.200700235
   de Vrese M, 2008, ADV BIOCHEM ENG BIOT, V111, P1, DOI 10.1007/10_2008_097
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2
   Gooneratne NS, 2008, CLIN GERIATR MED, V24, P121, DOI 10.1016/j.cger.2007.08.002
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Kern E, 2007, WIEN MED WOCHENSCHR, V157, P337, DOI 10.1007/s10354-007-0435-5
   LADAS EJ, 2010, RANDOMIZED CONTROLLE, V0, P0, DOI DOI 10.1002/CNCR.24723
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P237, DOI 10.1007/s00520-001-0329-9
   MORROW GR, 1982, NEW ENGL J MED, V307, P1476, DOI 10.1056/NEJM198212093072402
   Naeim A, 2008, J CLIN ONCOL, V26, P3903, DOI 10.1200/JCO.2007.15.9533
   Oberbaum M, 2001, CANCER, V92, P684, DOI 10.1002/1097-0142(20010801)92:3<684::AID-CNCR1371>3.0.CO;2-#
   Park J, 2008, J ALTERN COMPLEM MED, V14, P871, DOI 10.1089/acm.2008.SAR-4
   RASHAD UM, 2008, J LARYNGOL OTOL, V19, P1
   RIEMANN D, 2003, DIAGNOSTISCHE THERAP, V74, P456
   Rocha FCM, 2008, EUR J CANCER CARE, V17, P431, DOI 10.1111/j.1365-2354.2008.00917.x
   Röder C, 2004, FORTSCHR NEUROL PSYC, V72, P330, DOI 10.1055/s-2003-812513
   Scarpace SL, 2009, PHARMACOTHERAPY, V29, P578, DOI 10.1592/phco.29.5.578
   Shen YHA, 2009, CAN FAM PHYSICIAN, V55, P143
   SONTAKKE T, 2003, INDIAN J PHARM, V35, P32
   Strasser F, 2006, J CLIN ONCOL, V24, P3394, DOI 10.1200/JCO.2005.05.1847
   Wagner LI, 2004, BRIT J CANCER, V91, P822, DOI 10.1038/sj.bjc.6602012
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Worthington HV, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000978.pub3
   WORTHINGTON HV, 2007, COCHRANE DATABASE SY, V17, P0
   YAMAMOTO D, 2008, J CLIN ONCOL S, V155, P20615
   Youle M, 2007, HIV MED, V8, P241, DOI 10.1111/j.1468-1293.2007.00467.x
   Zick SM, 2009, SUPPORT CARE CANCER, V17, P563, DOI 10.1007/s00520-008-0528-8
   Zidan J, 2006, MED ONCOL, V23, P549, DOI 10.1385/MO:23:4:549
NR 45
TC 1
Z9 1
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0947-8965
EI 1433-0415
J9 ONKOLOGE
JI Onkologe
PD AUG 15
PY 2010
VL 16
IS 8
BP 795
EP 801
DI 10.1007/s00761-010-1819-5
PG 7
WC Oncology
SC Oncology
GA 643IO
UT WOS:000281289000009
DA 2026-01-16
ER

PT J
AU Lu, WD
   Rosenthal, DS
AF Lu, Weidong
   Rosenthal, David S.
TI Recent Advances in Oncology Acupuncture and Safety Considerations in Practice
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Editorial Material
ID controlled-trial; cancer-patients; breast-cancer; symptoms; therapy; xerostomia; management
AB Oncology acupuncture is a new and emerging field of research. Recent advances from published clinical trials have added evidence to support the use of acupuncture for symptom management in cancer patients. Recent new developments include (1) pain and dysfunction after neck dissection; (2) radiation-induced xerostomia in head and neck cancer; (3) aromatase inhibitor-associated arthralgia in breast cancer; (4) hot flashes in breast cancer and prostate cancer; and (5) chemotherapyinduced neutropenia in ovarian cancer. Some interventions are becoming a non-pharmaceutical option for cancer patients, while others still require further validation and confirmation. Meanwhile, owing to the rapid development of the field and increased demands from cancer patients, safety issues concerning oncology acupuncture practice have become imperative. Patients with cancer may be at higher risk developing adverse reactions from acupuncture. Practical strategies for enhancing safety measures are discussed and recommended.
C1 [Lu, Weidong; Rosenthal, David S.] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute
RP Lu, WD (corresponding author), Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, SW560,44 Binney St, Boston, MA 02115 USA.
EM Weidong_lu@dfci.harvard.edu
FU NCCIH NIH HHS [5K01AT004415, K01 AT004415] Funding Source: Medline
CR Ashamalla H, 2011, INT J RADIAT ONCOL, V79, P1358, DOI 10.1016/j.ijrobp.2010.01.025
   Beer TM, 2010, UROLOGY, V76, P1182, DOI 10.1016/j.urology.2010.03.033
   BLOM M, 1992, ORAL SURG ORAL MED O, V73, P293, DOI 10.1016/0030-4220(92)90124-9
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Garcia MK, 2009, HEAD NECK-J SCI SPEC, V31, P1360, DOI 10.1002/hed.21110
   Ge AXY, 2010, J ALTERN COMPLEM MED, V16, P811, DOI 10.1089/acm.2009.0456
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Sun Bao-Mu, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P641
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   White Adrian, 2004, ACUPUNCT MED, V22, P122
NR 17
TC 44
Z9 51
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD DEC 15
PY 2010
VL 11
IS 3-4
BP 141
EP 146
DI 10.1007/s11864-010-0126-0
PG 6
WC Oncology
SC Oncology
GA 691SJ
UT WOS:000285100800011
PM 21103962
DA 2026-01-16
ER

PT J
AU Pfister, DG
   Cassileth, BR
   Deng, GE
   Yeung, KS
   Lee, JS
   Garrity, D
   Cronin, A
   Lee, N
   Kraus, D
   Shaha, AR
   Shah, J
   Vickers, AJ
AF Pfister, David G
   Cassileth, Barrie R
   Deng, Gary E
   Yeung, K Simon
   Lee, Jennifer S
   Garrity, Donald
   Cronin, Angel
   Lee, Nancy
   Kraus, Dennis
   Shaha, Ashok R
   Shah, Jatin
   Vickers, Andrew J
TI Acupuncture for pain and dysfunction after neck dissection: results of a
SO Journal of clinical oncology : official journal of the American Society of
LA English
DT Journal Article
AB PURPOSE: To determine whether acupuncture reduces pain and dysfunction in  patients with cancer with a history of neck dissection. The secondary objective  is to determine whether acupuncture relieves dry mouth in this population.  PATIENTS AND METHODS: Patients at a tertiary cancer center with chronic pain or  dysfunction attributed to neck dissection were randomly assigned to weekly  acupuncture versus usual care (eg, physical therapy, analgesia, and/or  anti-inflammatory drugs, per patient preference or physician recommendation) for  4 weeks. The Constant-Murley score, a composite measure of pain, function, and  activities of daily living, was the primary outcome measure. Xerostomia, a  secondary end point, was assessed using the Xerostomia Inventory. RESULTS:  Fifty-eight evaluable patients were accrued and randomly assigned from 2004 to  2007 (28 and 30 patients on acupuncture and control arms, respectively).  Constant-Murley scores improved more in the acupuncture group (adjusted  difference between groups = 11.2; 95% CI, 3.0 to 19.3; P = .008). Acupuncture  produced greater improvement in reported xerostomia (adjusted difference in  Xerostomia Inventory = -5.8; 95% CI, -0.9 to -10.7; P = .02). CONCLUSION:  Significant reductions in pain, dysfunction, and xerostomia were observed in  patients receiving acupuncture versus usual care. Although further study is  needed, these data support the potential role of acupuncture in addressing  post-neck dissection pain and dysfunction, as well as xerostomia.
C1 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. pfisterd@mskcc.org
NR 0
TC 0
SN 1527-775
EI 0732-183
J9 J Clin Oncol
PD APR 22
PY 2010
VL 28
IS 15
BP 2565
EP 70
DI 10.1200/JCO.2009.26.9860
PG -2495
WC Acupuncture Therapy; methods; Aged; Female; Head and Neck Neoplasms; surgery; Humans; Male; Middle Aged; Neck Dissection; adverse effects; Neck Pain; etiology; Pain, Postoperative; etiology; Xerostomia; complications
UT PubMed:20406930
PM 20406930
DA 2010-04-22
ER

PT J
AU Ge, AX
   Ryan, ME
   Giaccone, G
   Hughes, MS
   Pavletic, SZ
AF Ge, Adeline X Y
   Ryan, Mary E
   Giaccone, Giuseppe
   Hughes, Marybeth S
   Pavletic, Steven Z
TI Acupuncture treatment for persistent hiccups in patients with cancer.
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
AB OBJECTIVE: The objective of this study was to investigate the effects of  acupuncture treatment for persistent hiccups in cancer patients. DESIGN: The  study design was a retrospective case series. SETTINGS/LOCATION: The study  setting was the Clinical Research Center of the National Institutes of Health.  SUBJECTS: The subjects were 16 adult male patients ages 27-71 with cancer, with  persistent hiccups. INTERVENTIONS: There were one to three acupuncture sessions  over a 1-7-day period. OUTCOME MEASURES: Treatment efficacy was measured using a  hiccup assessment instrument pre- and post-treatment. The effects of acupuncture  on common symptoms reported by all patients were also evaluated. RESULTS:  Thirteen (13) patients experienced complete remission of persistent hiccups (p <  0.0001); 3 patients experienced decreased hiccups severity. Significant  improvement was observed in discomfort (p < 0.0001), distress (p < 0.0001), and  fatigue (p = 0.0078). CONCLUSIONS: This case series demonstrates that acupuncture  may be a clinically useful, safe, and low-cost therapy for persistent hiccups in  patients with cancer.
C1 Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA.age@mail.nih.gov
NR 0
TC 0
SN 1557-770
EI 1075-553
J9 J Altern Complement Med
PD JUN 26
PY 2010
VL 16
IS 7
BP 811
EP 6
DI 10.1089/acm.2009.0456
PG -805
WC Acupuncture Therapy; Adult; Aged; Fatigue; etiology; Hiccup; classification; Humans; Male; Middle Aged; Neoplasms; complications; Pain; etiology; Pain Management; Remission Induction; Retrospective Studies; Severity of Illness Index; Stress, Psychological; etiology; Treatment Outcome
UT PubMed:20575702
PM 20575702
DA 2010-06-26
ER

PT J
AU Omura, Y
   Chen, YM
   Lermand, O
   Jones, M
   Duvvi, H
   Shimotsuura, Y
AF Omura, Yoshiaki
   Chen, Yemeng
   Lermand, Olivia
   Jones, Marilyn
   Duvvi, Harsha
   Shimotsuura, Yasuhiro
TI Effects of Transcutaneous Electrical Stimulation (1 pulse/sec) Through Custom-made Disposable Surface Electrodes Covering Omura's ST36 Area of Both Legs on Normal Cell Telomeres, Oncogen C-fosAb2, Integrin α5β1, Chlamydia Trachomatis, etc. in Breast Cancer & Alzheimer Patients
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Electrical stimulation; Transcutaneous Electrical Stimulation; Breast cancer; Alzheimer's Disease, beta-Amyloid (1-42); Diabetic gangrene of lower extremities; Telomere; Chlamydia trachomatis; Oncogen C-fosAb2; Integrin alpha(5)beta(1); Pain
ID o-ring test; test molecular-identification; cardiac troponin-i; internal organs; acupuncture points; circulatory disturbances; cephalic hypertension; hypotension syndrm; clinical-applications; viral transformation
AB Our previous study indicated that when extremely reduced normal cell (NC) telomeres in various cancer patients are increased over 500ng BDORT units, abnormally high cancer cell telomeres and cancer-related markers such as Oncogen C-fosAb2 (Onco.) & Integrin alpha(5)beta(1) (Integ.), & 8-OH-dG as well as bacterial & viral infections, mercury, asbestos, chromium, & beta-amyloid (1-42) markedly reduced due to improved circulation & excretion of these substances in urine. Since 1995, we have been using press-needle stimulation of Omura's ST36 with 200x press-release procedure 4x a day, with significant improvements in various cancer patients. In this study, Transcutaneous Electrical Stimulation (TES) at 60 pulses/min, which is close to patient's heart rate, was given between Omura's ST36 of both legs of the breast cancer & Alzheimer's patients. After about 10 minutes of TES, NC telomeres increased from 1yg (=10(-24)g) to 500 similar to 525ng; Integ. reduced from 85 similar to 75ng to 0.5ng & Chlamydia trachomatis (CT) reduced from 4500 similar to 3500ng to 0.5ng. An additional 10 minutes TES increased NC telomeres to 800-875ng, while Integ. reduced to 0.5yg & CT became less than 0.1yg. After a total 30 minutes of TES, NC telomeres increased to 1000-1200ng BDORT units, with decreases in Integ. and Onco. to less than 0.1yg. CT reduced to <<0.1yg. About 24 hours later, NC telomeres were still 300ng & both Integ. and Onco. were 2.5ng. CT was similar to 20ng. In Alzheimer patient, abnormally high beta-Amyloid (1-42) of 7-12ng markedly reduced to within normal value of less than 1.5ng by 20 similar to 30 min TES. Stimulation beyond 30 minutes gradually reduced NC telomeres. TES pulse rate of 4 pulses/sec for the same patient initially increased NC telomere up to 750-950ng BDORT units within 20 minutes, but when stimulation continued more than 20 min, NC telomeres rapidly reduced to similar to 150ng in less than 10 min of TES with reduced beneficial effects.
C1 [Duvvi, Harsha] New York Med Coll, Dept Family & Community Med, Valhalla, NY 10595 USA.
   [Omura, Yoshiaki] Manhattan Coll, Dept Elect Engn, New York, NY USA.
   [Omura, Yoshiaki] Univ Paris, Univ Paris 05, Paris, France.
   [Chen, Yemeng] New York Coll Tradit Chinese Med, New York, NY USA.
   [Chen, Yemeng] New York State Board Acupuncture, New York, NY USA.
   [Chen, Yemeng] Shanghai Med Univ, Acupuncture Clin, Shanghai, Peoples R China.
   [Lermand, Olivia] St Lukes Roosevelt Hosp, New York, NY USA.
   [Jones, Marilyn] Wholist Dent Ctr Houston, Houston, TX USA.
   [Jones, Marilyn] Univ Houston, Houston, TX 77004 USA.
   [Shimotsuura, Yasuhiro] Japan Bi Digital O Ring Test Assoc, Kurume, Fukuoka, Japan.
C3 New York Medical College; Manhattan University; Universite Paris Cite; Fudan University; Mount Sinai Morningside; Mount Sinai West; University of Houston System; University of Houston
RP Omura, Y (corresponding author), 800 Riverside Dr 8-I, New York, NY 10032 USA.
EM icaet@yahoo.com
CR CASTO BC, 1976, P AM ASSOC CANC RES, V17, P12
   Charlton JE, 2005, CORE CURRICULUM FOR PROFESSIONAL EDUCATION IN PAIN, V0, P1
   DiPaolo J A, 1978, NATL CANCER INST MONOGR, V0, P245
   FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6
   FUKUDA S, 2000, ACUPUNCTURE ELECTRO, V25, P221
   Gibb HJ, 2000, AM J IND MED, V38, P115, DOI 10.1002/1097-0274(200008)38:2<115::AID-AJIM1>3.0.CO;2-Y
   HATCH GG, 1983, CANCER RES, V43, P1945
   Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212
   LEVIN MF, 1993, ARCH PHYS MED REHAB, V74, P54
   MILLER FR, 1979, JNCI-J NATL CANCER I, V63, P1457
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P139, DOI 10.3727/036012985816714469
   OMURA Y, 1981, ACUPUNCTURE ELECTRO, V6, P109, DOI 10.3727/036012981816952234
   OMURA Y, 1980, ACUPUNCTURE ELECTRO, V5, P1
   OMURA Y, 1978, ACUPUNCTURE ELECTRO, V3, P223
   Omura Y, 2005, ACUPUNCTURE ELECTRO, V30, P219, DOI 10.3727/036012905815901226
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P219, DOI 10.3727/036012986816359003
   Omura Y, 2004, ACUPUNCTURE ELECTRO, V29, P1
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P65, DOI 10.3727/036012986816359201
   OMURA Y, 1988, ACUPUNCTURE ELECTRO, V13, P153, DOI 10.3727/036012988816358606
   OMURA Y, 1995, ACUPUNCTURE ELECTRO, V20, P21
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P255, DOI 10.3727/036012985816714423
   OMURA Y, 1982, ACUPUNCTURE ELECTRO, V7, P209, DOI 10.3727/036012982816952026
   OMURA Y, 1978, ACUPUNCTURE ELECTRO, V3, P1
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P335, DOI 10.3727/036012985816714405
   OMURA Y, 1977, ACUPUNCTURE AND ELECTRO-THERAPEUTICS RESEARCH, V2, P161
   OMURA Y, 1994, ACUPUNCTURE ELECTRO, V19, P39, DOI 10.3727/036012994816357394
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P127, DOI 10.3727/036012986816359193
   Omura Y, 1998, ACUPUNCTURE ELECTRO, V23, P185, DOI 10.3727/036012998816356472
   OMURA Y, 1989, ACUPUNCTURE ELECTRO, V14, P155, DOI 10.3727/036012989816358470
   OMURA Y, 1975, ACUPUNCTURE AND ELECTRO-THERAPEUTICS RESEARCH, V1, P157
   OMURA Y, 1975, ACUPUNCTURE AND ELECTRO-THERAPEUTICS RESEARCH, V1, P231
   OMURA Y, 1983, ACUPUNCTURE ELECTRO, V8, P177
   OMURA Y, 1984, ACUPUNCTURE ELECTRO, V9, P187
   OMURA Y, 1987, ACUPUNCTURE ELECTRO, V12, P201, DOI 10.3727/036012987816358788
   OMURA Y, 1989, ACUPUNCTURE ELECTRO, V14, P61, DOI 10.3727/036012989816358506
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601
   OMURA Y, 1979, P NAT S AC MOX AC AN, V0, P0
   OMURA Y, 2008, ACUPUNCTURE ELECTRO, V33, P78
   OMURA Y, 2000, ACUPUNCTURE ELECT TH, V25, P208
   OMURA Y, 2000, PRATICA TESTE ANEL B, V0, P0
   Omura Y, 1993, ACUPUNCTURE ELECTRO, V19, P248
   Omura Y, 1975, ACUPUNCT. ELECTRO-THER. RES, V1, P51
   OMURA Y, 1978, S PHYS MECH AC MOX 5, V0, P81
   Omura Y, 1985, ACUPUNCTURE ELECTRO, V10, P1
   OMURA Y, 2002, P BRIDG WORLDS FILL, V0, P150
   Omura Y, 2009, 19 ANN S JAP BI DIG, V0, P15
   Omura Y, 1990, 4 WORLD C SCI AC ICM, V0, P42
   OMURA Y, 1979, J JAPAN ACUPUNCTURE, V27, P310
   Omura Y, 1999, 10 ANN S BI DIG O RI, V0, P32
   OMURA Y, 2005, 15 ANN SCI M JAP BI, V0, P0
   OMURA Y, 1980, PAIN BASIC RES TREAT, V0, P360
   OMURA Y, 2002, JAPANESE J ACUPUNCTU, V61, P143
   Omura Y, 2000, 4 INT S BID O RING T, V25, P0
   Omura Y, 1997, FUTURE MED O RING TE, V0, P341
   Omura Y, 2001, ACUPUNCTURE ELECTRO, V26, P77
   OMURA Y, 2000, 4 INT S BI DIG O RIN, V0, P204
   OMURA Y, 1997, PRACTICE BI DIGITAL, V0, P0
   Omura Y, 2001, JAPANESE J ACUPUNCTU, V692, P129
   OMURA Y, 2002, ACUPUNCTURE ELECTRO, V27, P237
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V19, P234
   Omura Y, 2008, ACUPUNCTURE ELECTRO, V33, P231
   Omura Y, 1983, ELECTROACUPUNTURA Y, V0, P0
   Omura Y, 2008, ACUPUNCTURE ELECTRO, V33, P227
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P235, DOI 10.3727/036012907815844066
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P31, DOI 10.3727/036012907815844174
   Omura Y, 2006, ACUPUNCTURE ELECTRO, V31, P247
   Omura Y, 2006, ACUPUNCTURE ELECTRO, V31, P61, DOI 10.3727/036012906815844300
   Omura Y, 2010, ACUPUNCTURE ELECTRO, V35, P45, DOI 10.3727/036012910803860977
   Omura Y, 2009, ACUPUNCTURE ELECTRO, V34, P41, DOI 10.3727/036012909803861059
   TSAPAKOS MJ, 1983, CANCER RES, V43, P5662
NR 78
TC 14
Z9 14
U1 0
U2 12
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2010
VL 35
IS 3-4
BP 147
EP 185
DI 10.3727/036012910803860922
PG 39
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA 704UU
UT WOS:000286081900003
PM 21319603
DA 2026-01-16
ER

PT J
AU Dean-Clower, E
   Doherty-Gilman, AM
   Keshaviah, A
   Baker, F
   Kaw, C
   Lu, W
   Manola, J
   Penson, RT
   Matulonis, UA
   Rosenthal, DS
AF Dean-Clower, Elizabeth
   Doherty-Gilman, Anne M
   Keshaviah, Aparna
   Baker, Frank
   Kaw, Chiewkwei
   Lu, Weidong
   Manola, Judith
   Penson, Richard T
   Matulonis, Ursula A
   Rosenthal, David S
TI Acupuncture as palliative therapy for physical symptoms and quality of life for
SO Integrative cancer therapies
LA English
DT Journal Article
AB BACKGROUND: Acupuncture is underutilized as an adjunct cancer therapy. The main  study objectives were to determine the feasibility of administering acupuncture  as palliative therapy to patients with advanced ovarian or breast cancer and to  assess the effect on symptoms and quality of life (QOL). METHODS: This study was  a pilot, single-armed prospective clinical trial for patients with advanced  cancer to receive 12 acupuncture sessions over 8 weeks with follow-up at weeks 9  and 12. Ambulatory patients with advanced ovarian or breast cancer were enrolled  to receive treatments at an outpatient academic oncology center. Symptom severity  was measured before and after each acupuncture session.A composite QOL assessment  tool, consisting of validated instruments, was completed at 5 time points.  RESULTS: Forty patients enrolled in the study. Twenty-eight patients (70%; 95%  confidence interval [CI] = 53%-83%) completed 4 weeks of treatment, and 26  patients (65%; 95% CI = 48%-79%) completed 8 weeks. Eight patients (20%) withdrew  before receiving acupuncture, and 6 patients (15%) discontinued treatment early  because of disease progression or scheduling demands. Among all 32 assessed  patients, there was self-reported improvement immediately post-treatment in  anxiety,fatigue, pain, and depression and significant improvement over time for  patients with anxiety (P = .001) and depression(P = .02). Among patients  experiencing baseline symptoms, there was improvement in anxiety (P = .001),  fatigue (P = .0002),pain (P = .0002), and depression (P = .003). QOL measures of  pain severity and interference, physical and psychological distress, life  satisfaction, and mood states showed improved scores during treatment, with  sustained benefit at 12 weeks. CONCLUSIONS: This pilot study demonstrates that an  8-week outpatient acupuncture course is feasible for advanced cancer patients and  produces a measurable benefit that should be evaluated in controlled trials.
C1 Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, USA.
NR 0
TC 0
SN 1552-695
EI 
J9 Integr Cancer Ther
PD MAY 21
PY 2010
VL 9
IS 2
BP 158
EP 67
DI 10.1177/1534735409360666
PG -91
WC Acupuncture Therapy; methods; Adult; Aged; Ambulatory Care; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; physiopathology; Palliative Care; methods; Pilot Projects; Prospective Studies; Quality of Life; Severity of Illness Index; Time Factors
UT PubMed:20483875
PM 20483875
DA 2010-05-21
ER

PT J
AU Dios, PD
   Lestón, JS
AF Diz Dios, Pedro
   Seoane Leston, Juan
TI Oral cancer pain
SO ORAL ONCOLOGY
LA English
DT Review
DE Oral cancer; Pain; Analgesic; Opioid; Neural blockade
ID quality-of-life; epidural morphine; carcinoma; surgery; relief; head
AB Pain may be the initial symptom in oral cancer, and is a common complaint both in patients awaiting treatment and in those already in treatment. However, little has been published in the literature on the management of oral cancer pain. Effective pain control requires a multimodal approach in which pharmacological management based on the World Health Organization (WHO) analgesic ladder continues to play an essential role. Although different routes are available for the administration of analgesics, oral delivery continues to be the principal route for pain control in the. first instance. Interventional approaches include blockade of a peripheral nerve or of the relevant ganglion, and the use of central neuraxial blockade. The intraventricular or intrathecal administration of opioids, with or without local anaesthetics, has been indicated for severe intractable pain. The development of new treatment modalities provides additional options, though further clinical research is required. There is no evidence of the efficacy of non-pharmacological methods such as acupuncture or transcutaneous nerve stimulation in the management of oral cancer pain. Surgery, radiation therapy, and chemotherapy have also been suggested, but their results have not been quantified. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Diz Dios, Pedro; Seoane Leston, Juan] Univ Santiago de Compostela, Sch Med & Dent, Santiago De Compostela 15782, A Coruna, Spain.
C3 Universidade de Santiago de Compostela
RP Dios, PD (corresponding author), Univ Santiago de Compostela, Sch Med & Dent, C Entrerrios Sn, Santiago De Compostela 15782, A Coruna, Spain.
EM pedro.diz@usc.es
CR Unknown -, 1979, PAIN, V6, P249
   Unknown -, 1994, MANAGEMENT OF CANCER PAIN, V0, P0
   Unknown -, 1990, WORLD HEALTH ORGAN TECH REP SER, V804, P1
   Buchsel PC, 2008, EXPERT OPIN DRUG MET, V4, P1449, DOI 10.1517/17425255.4.11.1449
   Clarkson J, 2007, COCHRANE DB SYST REV, V2, P0
   Cuffari L, 2006, ORAL SURG ORAL MED O, V102, P56, DOI 10.1016/j.tripleo.2005.10.041
   Datta Sukdeb, 2006, ORAL MAXILLOFAC SURG CLIN NORTH AM, V18, P627
   Epstein JB, 1999, HEAD NECK-J SCI SPEC, V21, P1
   EPSTEIN JB, 1993, ORAL ONCOL, V29B, P191, DOI 10.1016/0964-1955(93)90022-7
   FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205
   Gorsky M, 2004, ORAL SURG ORAL MED O, V98, P546, DOI 10.1016/j.tripleo.2003.12.041
   GROND S, 1991, J PAIN SYMPTOM MANAG, V6, P411, DOI 10.1016/0885-3924(91)90039-7
   JENSEN OM, 1991, ADV OTO-RHINO-LARYNG, V46, P124
   Kanpolat Y, 2008, NEUROSURGERY, V63, P147, DOI 10.1227/NEU.0000320139.27501.69
   Kayahara H, 2000, BRIT J ORAL MAX SURG, V38, P546, DOI 10.1054/bjom.2000.0476
   Kohase H, 2002, ORAL SURG ORAL MED O, V94, P162, DOI 10.1067/moe.2002.124857
   LAZORTHES Y, 1998, TXB STEREOTACTIC FUN, V0, P1477
   Linsen S, 2009, J PAIN SYMPTOM MANAG, V37, P94, DOI 10.1016/j.jpainsymman.2006.12.019
   Logan RM, 2009, ORAL ONCOL, V45, P844, DOI 10.1016/j.oraloncology.2009.03.018
   Marshall J A, 1997, DENT CLIN NORTH AM, V41, P355
   MCGRATH PA, 1990, PAIN CHILDREN NATURE, V0, P88
   Nagamine K, 2006, J PAIN, V7, P659, DOI 10.1016/j.jpain.2006.02.013
   NARAYANAN RS, 1988, HEADACHE, V28, P258, DOI 10.1111/j.1526-4610.1988.hed2804258.x
   Rogers SN, 2004, HEAD NECK-J SCI SPEC, V26, P54, DOI 10.1002/hed.10351
   Rosell Monica, 2007, V5, V0, PP31, DOI 10.1007/698_5_069
   SAMEK M, 1990, DEUT ZAHNAERZTL Z, V45, P49
   Schliephake H, 2002, INT J ORAL MAX SURG, V31, P427, DOI 10.1054/ijom.2001.0194
   Scully C, 2006, ORAL DIS, V12, P229, DOI 10.1111/j.1601-0825.2006.01258.x
   Singhal AK, 2006, ACTA ANAESTH SCAND, V50, P234, DOI 10.1111/j.1399-6576.2006.00924.x
   TEOH N, 1992, WHO CANC PAIN RELIEF, V0, P5
   Ulrich H P, 1989, DTSCH Z MUND KIEFER GESICHTSCHIR, V13, P349
NR 33
TC 26
Z9 30
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JUN 15
PY 2010
VL 46
IS 6
BP 448
EP 451
DI 10.1016/j.oraloncology.2010.02.017
PG 4
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 607UY
UT WOS:000278533700016
PM 20308009
DA 2026-01-16
ER

